

i3S/Ipatimup, University of Porto  
Rua Alfredo Allen, 208, 4200-135 Porto  
Portugal. Lab 208S4 - 2nd floor

+351 225570785; carlaol@ipatimup.pt

<https://www.i3s.up.pt/research-group.php?groupid=18>

ResearcherID-F-8188-2011; ORCID-0000-0001-8340-2264; Scopus-7102223149; Ciência ID: 3011-EA6C-B5A3

Last Update: October, 2022



# Carla Oliveira, BSc, PhD

## EDUCATION AND TRAINING

- 2004 – 2005 Postdoc fellow (D Huntsman's lab), Pathol. Dept. Laboratory Medicine, UBC, Vancouver, CA
- 2002 – 2004 Postdoc fellow (R Seruca's lab and Richard Hamelin's lab), Ipatimup, Porto, PT & INSERM, Paris, FR
- Mar, 2002 Ph.D. in Human Biology, GABBA Ph.D. Program, Medical Fac, Univ. Porto, Portugal
- 2001 – 2002 Visiting Ph.D. student, Ipatimup-Institute of Molecular Pathology and Immunology (Raquel Seruca's Lab), UPorto, PT
- 1998 – 2000 Ph.D. student, CIMR - Cambridge Institute for Medical Research (Carlos Caldas Lab), Cambridge Univ., UK
- 1998 – 1999 Graduate Program in Areas of Basic and Applied Biology - GABBA Ph.D. Program
- 1995 – 1996 Degree Training at IBILI, Fac. Science and Tech, Univ. Coimbra, Portugal
- 1991 – 1995 Biochemistry Degree (4 years undergraduate studies), Faculty of Science and Technology, Univ. Coimbra, Portugal

## FELLOWSHIPS

- 2011 – 2012 Sabbatical fellowship (bsab/1311870456/2011) Science and Technology Foundation (FCT), PT
- 2005 Travel fellowship from European Association for Cancer Research (EACR) to Vancouver, CA
- 2002 – 2005 Post-doctoral fellowship (SFRH/BPD/9463/2002), FCT, PT
- 1997 – 2002 GABBA Ph.D. Program studentship (PRAXIS XXI/BD/13378/97), FCT, PT
- 1997 FCT Trainee fellowship (PRAXIS XXI), Cancer Genetics Group - Ipatimup, Porto, PT

## CURRENT AND PREVIOUS POSITIONS

- 2015 – present Principal Investigator, Expression Regulation in Cancer Group, i3S, Porto, PT
- 2013 – present Principal Investigator, Expression Regulation in Cancer Group, Ipatimup, Porto, PT
- 2013 – present Founder/CEO Bioinformatics Start-up Company Bioinf2Bio, Porto, PT | <http://bit.ly/2lq5DY8>
- 2011 – 2012 Guest Scientist, Max Planck Institute for Developmental Biology, Tuebingen, DE
- 2011 Tenure-track Group Leader, Ipatimup, Porto, PT
- 2008 - 2012 Financially Independent Researcher – FCT Program Ciência 2007 - in Cancer Genetics Group, IPATIMUP, Porto, PT
- 2003 – present Affiliated Professor, Dept. Pathology/Oncology, Medical Faculty UPorto, PT | [www.med.up.pt](http://www.med.up.pt)
- 2005 – 2007 Auxiliary Investigator, Cancer Genetics Group, Ipatimup, Porto, PT
- 2005 – present Consultant for cancer-associated syndromes, Ipatimup Diagnostics Unit
- 2002 – 2005 Auxiliary Professor of Biochemistry, Univ. Fernando Pessoa, Porto, PT

## INSTITUTIONAL RESPONSIBILITIES

- 2013 – present Member of the Scientific Committee of Ipatimup and i3S, Porto, PT  
2008 – present Member of the Advisory Board of 3 Postdoc fellows and 6 Ph.D. students

## ADVANCED TRAINING ACTIVITIES

### **Regular Participation (Faculty and/or Supervisor) in Post-Graduate and Graduate Programs:**

- 2022-Present Responsible for the curricular unit "Biomedical and Bioinformatics Research I" in the 1<sup>st</sup> Degree in Digital Health and Translational Medicine from FMUP, Univ. Porto, Porto PT
- 2022-Present Co-responsible for the curricular unit "Biomedical and Bioinformatics Research II" in the 1<sup>st</sup> Degree in Digital Health and Translational Medicine from FMUP, Univ. Porto, Porto PT
- 2022-Present Co-responsible for the curricular unit "Project in Human Biology" in the 1<sup>st</sup> Degree in Digital Health and Translational Medicine from FMUP, Univ. Porto, Porto PT
- 2019-Present Faculty and Supervisor, PhD Programme in Business Administration, Univ. Minho, Braga, PT
- 2019-Present Faculty and Supervisor, Doctoral Program in Molecular and Cell Biology (MCbiology), ICBAS, Univ. Porto, PT
- 2017-2019 Faculty and Supervisor, Bioinformatics Master Program, Univ. Minho, Braga, PT
- 2016-Present Faculty and co-Organizer, European Society of Human Genetics-ESHG Biennial Course in Hereditary Cancer Genetics, Univ. Residential Centre Bertinoro, IT
- 2014-Present Faculty and Supervisor, BiotechHealth - Doctoral Program on Cellular and Molecular Biotechnology Applied to Health Sciences, Porto, PT
- 2013-2019 Faculty, Biomedical Engineer Doctoral Program, Univ. Minho, Braga, PT
- 2013-2019 Faculty and Supervisor, Biomedical Engineer Doctoral Program, FEUP, Porto, PT
- 2012-2017 Faculty and Supervisor, Biomedicine Doctoral Program, Univ. Aveiro, Aveiro, PT
- 2011 – present Faculty, Ipatimup, "Genomics and Transcriptomics", Workshop in Cancer Research. Porto, PT
- 2008-Present Faculty and Supervisor, Oncology Master Program, ICBAS, Porto, PT
- 2005-Present Faculty and Supervisor, Doctoral Program in Molecular Medicine and Oncology (PDMOM), FMUP, Univ. Porto, PT
- 2005-Present Faculty and Supervisor, Medicine and Molecular Oncology Master (MOM) Program, FMUP, Porto, PT
- 2005-Present Faculty and Supervisor, Biomedicine Doctoral Program, FMUP, Porto, PT
- 2004-Present Faculty and Supervisor, GABBA PhD Program, Univ. Porto, PT
- 1995 – 1996 Monitor (volunteer), practical lessons of Molecular Biology delivered to of Biochemistry and Biology undergraduate students, Univ. Coimbra, PT

### **Sporadic Participation (Faculty and/or Supervisor) in other Post-Graduate Courses:**

1. University of Minho, Cancer therapy Course, "Functional genomics", Braga, PT
2. University of Minho, Epigenetics Course, "Expression regulation in cancer", Braga, PT
3. University of Coimbra, FMUC PhD Program in Health Sciences, Coimbra, Portugal
4. Gulbenkian PhD programs, Institute Calouste Gulbenkian, Oeiras, Portugal
6. NOVA Medical Sciences, NOVA University Doctoral program, Lisbon, PT
7. Faculty, IMMS-Guadalajara, "From disease to mechanisms", Doctoral Prog Hum. Genet, 2013, MEX

---

## COMMISSIONS OF TRUST (External evaluation, Advisory boards, Scientific and Management Committees)

- 2022-Present **Co/Responsible** of three curricular units, Degree in Digital Health and Translational Medicine, FMUP, UP, PT
- 2022 **Coordinator of the Evaluation Panel** on Experimental Biology and Biochemistry for PhD studentships selection, Portuguese Foundation for Science and technology, PT
- 2022 **Organizing Committee Member**, INTERNATIONAL GASTRIC CANCER CONGRESS 2022 | <https://gastriccancerconference.com/general-information/committees/>
- 2021-2022 **Member of the Portuguese Group of Hereditary Tumours** (PROGO) promoted by The Portuguese Society of Oncology | [www.cancrohereditario.pt](http://www.cancrohereditario.pt)
- 2021-2026 **Secretary General - Executive Board ESHG** - European Society of Human Genetics
- 2020 **Selection Committee**, Tenure-track positions, University of Barcelona, SP
- 2020 **External Evaluator**, La Marató de TV3, Agency for Health and Quality and Assessment of Catalonia, SP
- 2020 **External Evaluator**, Research Grants IPOL-Lisbon, PT
- 2020 **External Evaluator**, Research Grants Institut National du Cancer, INCa, FR
- 2020 **ERC Remote Referee**, European Research Council Executive Agency (ERCEA) for Starting Grants, Panel L4
- 2019-2023 **Member of the Scientific Advisory Board**, Integrated Cancer Research Site (Siric) Curamus, Sorbonne Université, Paris, FR
- 2019 **Review Panel Member** of research grant: Swiss Cancer League Grant, CH; French National Cancer Institute (INCa), FR
- 2018-2020 **Secretary of the General Assembly**, ASPIC - Portuguese Association for Cancer Research | <http://www.aspic.pt/en/page/committees>
- 2018 **Review Panel Member** of research grant: Fundo iMM-Laço Annual Research Grant, PT
- 2018-2019 **Member of the Committee for the Implementation of European Reference Centers in Portugal**, Appointed by the Portuguese Ministry of Health
- 2017-2020 **Chair of the Scientific Programme Committee**, SPGH – Portuguese Society of Human Genetics | <http://spgh.net/comissoes/comissao-cientifica/>
- 2017-2021 **Deputy Secretary General - Executive Board ESHG** - European Society of Human Genetics
- 2017-2022 **Scientific Programme Committee Member**, ESHG | <https://www.eshg.org/spc.0.html>
- 2017-2020 **Scientific Programme Committee Member**, XLI Jornadas Portuguesas de Genética SPG | <https://jornadasgenetica17.wixsite.com/ibimed/committees>
- 2018 **Scientific Committee Member**, ASPIC - 3<sup>rd</sup> ASPIC International Congress | <http://3rdcongress.aspic.pt/congress-committees>
- 2017-2018 **Faculty member**, Cancer Genetics group, European Society for Medical Oncology ESMO
- 2017 **Faculty member**, Inherited Cancer, 25th United European Gastroenterology Week 2017
- 2017 **Scientific Committee Member**, Conference “Risco Familiar de Cancro” | [www.ligacontracancro.pt/risco-familiar-de-cancro](http://www.ligacontracancro.pt/risco-familiar-de-cancro)
- 2017-present **Editorial Board member**, Applied Cancer Research, BMC-Springer Nature
- 2017 **Scientific Committee Member**, SINAL 2017 8<sup>th</sup> Meeting on Signal Transduction
- 2016-Present **Working Group Member**, ClinGen Genomic Clinical Variant Expert Curation Panel for CDH1 gene | <https://clinicalgenome.org/affiliation/50014/>
- 2015-2017 **Invited participant**, Oncology at the Limits Conference Series | [www.atthelimits.org/oncology](http://www.atthelimits.org/oncology)
- 2015-2017 **Scientific Committee Member**, Grupo Español Investigación Vesículas Extracelulares, GEIVEX
- 2014-Present **Founding Member and National Representative**, European Reference Network on “ERN Genetic tumour risk syndromes - GENTURIS” | [www.genturis.eu](http://www.genturis.eu)

- 2014-Present **Curator** of the LOVD database on “CDH1” variants
- 2014-Present **Member of the Abstract Reviewing Committee**, United European Gastroenterology Week
- 2014-2017 **Member of the Abstract Reviewing Committee**, ESHG | <https://www.eshg.org/>
- 2014 **Scientific Committee Member**, ASPIC | 1<sup>st</sup> ASPIC International Congress
- 2013-Present **Founding and Executive Committee Member** of the Consortium GENOME<sup>Portugal</sup>
- 2013-2017 **Management Committee Member**, BMBS COST Action BM1202 “Euro Network: Microvesicles and Exosomes in Health & Disease” | <http://bit.ly/2k2bKoM>
- 2011-present **Review Panel Member** of research grants: New Zealand Health Research Council; ICS-Institut Clinique de la Souris, FR; Dutch Cancer Society, NL; Foundation center le Cancer, BE
- 2011-present **Scientific Evaluation Panel Member** of Ph.D. and Post-doc fellowships and “Investigator FCT” applications for FCT-Portuguese Foundation of Science and Technology
- 2010-2017 **Scientific Programme Committee Member**, SPGH | <http://bit.ly/2InpOVP>
- 2010-2013 **Scientific Programme Committee Member**, ESHG | <https://www.eshg.org/spc.0.html>
- 1999-Present **Founding Member** of the International Gastric Cancer Linkage Consortium

---

## PARTICIPATION IN SCIENTIFIC NETWORKS

- 2023-2025 **PREVENTABLE Consortium**, EU funded project 2022
- 2019-2022 **1 Million Genomes Europe Consortium** – Portuguese branch
- 2016 – 2022 **Solve-RD Consortium**, EU funded project “Solve the unsolved – Rare Diseases” | [www.solve-rd.eu/](http://www.solve-rd.eu/)
- 2016 – Present **CANCEL STEM Consortium**, transnational team coordinated by Ipatimup to address the project “Tackling cancer stem cells: a challenge and an opportunity to advance in anti-cancer therapy”
- 2015 – Present **CANCER consortium**, transnational team coordinated by Ipatimup to address the project “Advancing cancer research: from basic knowledge to application”
- 2015 – Present **GEIVEX**, Grupo Español de Investigación en Vesículas Extracelulares | [www.geivex.org](http://www.geivex.org)
- 2015 – Present **TRAIN-EV consortium**, Marie Skłodowska-Curie Innovative Training Networks “Training in Extracellular vesicles: for benefit in Health & Disease” | [http://cordis.europa.eu/project/rcn/211790\\_en.html](http://cordis.europa.eu/project/rcn/211790_en.html)
- 2015 – Present **DOCnet consortium**, transnational team coordinated by Ipatimup to address the project “Diabetes & obesity at the crossroads between oncological and cardiovascular diseases – a system analysis network towards precision medicine”
- 2014 – Present **GENTURIS**, European Reference Network on Genetic Tumour Risk Syndromes | [www.genturis.eu](http://www.genturis.eu)
- 2013 – 2020 **GenomePT Consortium**, a Portuguese government funded infrastructure for sequencing “National Laboratory for Genome Sequencing and Analysis” | [ww.genomept.pt/copia-support](http://ww.genomept.pt/copia-support)
- 2013 – 2017 **ME-HAD Consortium**, BMBS COST Action BM1202 “European Network on Microvesicles and Exosomes in Health and Disease” | [www.cost.eu/COST\\_Actions/bmbs/BM1202](http://www.cost.eu/COST_Actions/bmbs/BM1202)
- 1999 – Present **IGCLC**, International Gastric Cancer Linkage Consortium

---

## RESEARCH TEAM, INTERESTS AND EXPERTIZE

**Current resident research team:** 2 Junior Researchers; 7 Ph.D. Students, 3 MSc student, 2 Bioinformatics and 1 Lab Manager.

**Research interest:** Regulatory mechanisms causing hereditary Gastric Cancer and models for their study. Identification of clinically relevant genotypic and phenotypic biomarkers in gastric cancer.

**Team expertize:** Human genetics, molecular and cell biology, Next Generation Sequencing and Bioinformatics; a strong link with hospitals which provides clinical expertise and patients’ biological material.

---

## FUNDING FOR RESEARCH PROJECTS

Principal Investigator (PI) (n=25 projects with a total budget of > 8M€):

25. "CANCER PREVENTION VS CANCER TREATMENT: THE RARE TUMOUR RISK SYNDROMES BATTLE" [PREVENTABLE], (Grant Ref. 101095483). **2023-2025**. Funded by Horizon Europe (HORIZON)- CALL HORIZON-HLTH-2022-CARE-08. **BUDGET: € 5.000.000,00** – Consortium coordinator
24. "HEREDITARY BREAST OVARIAN CANCER – HBOC\_II: OPTIMIZING HEREDITARY CANCER PATHWAYS (SAVING COSTS AND LIVES)". **2021-2023**. Funded by Fundação Amélia de Mello. **BUDGET: € 25.000,00**
23. "HEREDITARY BREAST OVARIAN CANCER – HBOC\_I: OPTIMIZING HEREDITARY CANCER PATHWAYS (SAVING COSTS AND LIVES)". **2021-2024**. Funded by CIA & EVITA Patients Association. **BUDGET: € 43.750,00**
22. "LIFE-TIME RISK ESTIMATIONS AND GENETIC MODIFIERS OF HEREDITARY DIFFUSE GASTRIC CANCER". [LEGOH], (Grant Ref. PTDC/BTM-TEC/6706/2020). **2021-2024**. Funded by Fundação para a Ciência e a Tecnologia. **BUDGET: € 249.951,25**
21. "COVID-19 DRIVEN NEUROLOGICAL PHENOTYPES". [NeuroCovid]. **2020-2021**. BIAL - PORTELA & C.ª, S.A. **BUDGET: €30.800,00** (PI at Ipatimup – Carla Oliveira; PI at Centro Hospitalar Universitário do Porto, Porto, Portugal - Manuel Correia; Total BUDGET: € 40.000,00).
20. "LONG SURVIVAL IN PATIENTS WITH HIGH-GRADE SEROUS CARCINOMA OF THE OVARY: A MOLECULAR AND CLINICAL STUDY" [OVARIO]. **2018-2019**. Funded by Instituto Português de Oncologia de Lisboa Francisco Gentil- E.P.E. (IPOLFG, E.P.E). **BUDGET: €38.000,00** (Co-PI Ipatimup – Carla Oliveira; Co-PI IPO Lisbon – Ana Felix)
19. "SOLVING THE 3D CHROMATIN STRUCTURE OF *CDH1* LOCUS TO IDENTIFY DISEASE-ASSOCIATED MECHANISMS" [3DChroMe], (Grant Ref. PTDC/BTM-TEC/30164/2017). **2018-2022**. Funded by Programa Operacional Competitividade e Internacionalização (through FEDER) and by Fundação para a Ciência e a Tecnologia. **BUDGET: €239.929,80**
18. "SOLVING THE UNSOLVED RARE DISEASES: HEREDITARY GASTRIC CANCER" [SolverRD], (Grant Ref. 779257). **2018-2022**. Funded by Horizon 2020 - Research and Innovation Framework Programme - H2020-SC1-2017-Single-Stage-RTD. **BUDGET: €250.000,00**
17. "NATIONAL LABORATORY FOR GENOME SEQUENCING AND ANALYSIS" [GenomePT], (Grant Ref. POCI-01-0145-FEDER-022184). **2017-2022**. Funded by Programa Operacional Competitividade e Internacionalização, Programa Operacional Regional de Lisboa, Programa Operacional Regional do Algarve (Portugal2020 and H2020, through FEDER) and by Fundação para a Ciência e a Tecnologia. **BUDGET: €251.109,61** (PIs at Ipatimup – Carla Oliveira and José Carlos Machado; Total BUDGET: € 502.219,21)
16. "TRAINING IN EXTRACELLULAR VESICLES: FOR BENEFIT IN HEALTH & DISEASE" [TRAIN-EV], (Grant Ref. 722148). **2017-2022**. Funded by Programme/Call: H2020-MSCA-ITN-2016 - Marie Skłodowska-Curie Innovative Training Networks. **BUDGET: €238.356,36**. The Beneficiary is Bioinf2Bio a Start-up of Ipatimup and Ipatimup is an Affiliated Institution.
15. "WP3 – CSC PLASTICITY: EMT AND STEM CELL STATE GENERATION" FROM "TACKLING CANCER STEM CELLS: A CHALLENGE AND AN OPPORTUNITY TO ADVANCE IN ANTI-CANCER THERAPY" [CANCERSTEM], (Grant Ref. POCI-01-0145-FEDER-016390). **2017-2021**. Funded by National funds through the FCT - Portuguese Science & Technology Foundation and co-funded by FEDER (Fundo Europeu de Desenvolvimento Regional) funds through the COMPETE 2020 - Operacional Programme for Competitiveness and Internationalization (POCI). **BUDGET: €85.640,00** (PI WP3 – Carla Oliveira)
14. "DIABETES & OBESITY AT THE CROSSROADS BETWEEN ONCOLOGICAL AND CARDIOVASCULAR DISEASES – A SYSTEM ANALYSIS NETWORK TOWARDS PRECISION MEDICINE" [DOCnet], (Grant Ref. NORTE-01-0145-FEDER-000003). **2016-2021**. Funded by NORTE2020 and FEDER (Fundo Europeu de Desenvolvimento Regional) funds through the COMPETE 2020 - Operacional Programme for Competitiveness and Internationalization (POCI) and Portugal 2020. **BUDGET: €122.352,00** (PI WP – Carla Oliveira)
13. "WP3 – TUMOUR SECRETED FACTORS IN EMT/NON-EMT CELLS FOR INVASION AND METASTIZATION", (Grant Ref. NORTE-01-0145-FEDER-000029). **2016-2019**. Funded by NORTE2020 and FEDER (Fundo

Europeu de Desenvolvimento Regional) funds through the COMPETE 2020 - Operacional Programme for Competitiveness and Internationalization (POCI) and Portugal 2020. **BUDGET: €124.876,00** (PI WP3 – Carla Oliveira)

12. “WP1 – MAPPING GENETIC AND PHENOTYPIC HETEROGENEITY IN HER2 POSITIVE CANCERS TO ANTICIPATE AND COUNTERACT RESISTANCE PHENOTYPES”, (Grant Ref. NORTE-01-0145-FEDER-000029). **2016-2019**. Funded by NORTE2020 and FEDER (Fundo Europeu de Desenvolvimento Regional) funds through the COMPETE 2020 - Operacional Programme for Competitiveness and Internationalization (POCI) and Portugal 2020. **BUDGET: €265.641,00** (PI WP1 – Carla Oliveira)
11. “THE INTRONIC REGULATION OF THE CDH1 GENE”; (Grant Ref. IntCDH1). **2016-2018**. Funded by the Ipatimup Board of Directors. **BUDGET: €25.000,00**
10. "THE ROLE OF GASTRIC CANCER CELL-DERIVED EXTRACELLULAR VESICLES"; (Grant Ref. GCEVs). **2016-2018**. Funded by the Ipatimup Board of Directors. **BUDGET: €25.000,00**
9. “A 3D MICROARRAY PLATFORM FOR THE HIGH-THROUGHPUT ANALYSIS OF THE ROLE OF THE EXTRACELLULAR MATRIX IN CANCER-ASSOCIATED EPITHELIAL-TO-MESENCHYMAL TRANSITIONS”. (Grant Ref. PTDC/BBB-ECT/2518/2014). **2016-2019**. Portuguese Science & Technology Foundation. **BUDGET: € 49.000,00** (co-PI at Ipatimup – Carla Oliveira; co-PI at INEB - Cristina Barrias; BUDGET: € 199.752,00)
8. “DEFINING THE CONTRIBUTION OF MUTATIONS IN CDH1 NON-CODING REGIONS AND OTHER KNOWN SUSCEPTIBILITY GENES TO HEREDITARY GASTRIC CANCER”. **2014-2016**. (Grant Ref. NSFC\_2014). Funded by the American association “NSFC - No Stomach for Cancer”. Collaboration and Partnership with David Huntsman from the BCCA, Vancouver Canada and the International Gastric Cancer Linkage Consortium (IGCLC). **BUDGET: \$ 50.000** (co-PI at Ipatimup – Carla Oliveira; co-PI at BCCA – David Huntsman)
7. “USING NGS TO UNCOVER STRUCTURAL AND REGULATORY VARIATION IN GASTRIC CANCER”, (Grant Ref. NGS GC\_2013). **2013-2016**. Funded by Coimbra Genomics and BGI. **BUDGET: € 90.000,00**
6. “TUMOR-TARGETED NANOPARTICLES FOR EARLY DIAGNOSIS OF GASTRIC CANCER” [TUMORTAG], (Grant Ref. PTDC/CTM-NAN/120958/2010). **2012-2015**. Funded by Portuguese Science & Technology Foundation. **BUDGET: € 153.895,00** (co-PI at Ipatimup)
5. “NEW E-CADHERIN RNAs: THE DARK SIDE OF A TUMOUR SUPPRESSOR GENE”, (Grant Ref. PTDC/SAU-GMG/110785/2009). **2011-2014**. Funded by Portuguese Science & Technology Foundation. **BUDGET: € 183.000,00**
4. “MUTATED SUPPRESSOR TRNAS AS A THERAPEUTIC TOOL FOR CANCER ASSOCIATED SYNDROMES: HDGC AS A MODEL”. **2009-2011**. Funded by Calouste Gulbenkian Foundation. **BUDGET: € 50.000,00**
3. “MICRORNAs IN GASTRIC CANCER”. **2009-2011**. Funded by IPATIMUP. **BUDGET: € 47.000,00**
2. “ROLE OF NOVEL REGULATORY MECHANISMS IN THE LOSS OF E-CADHERIN EXPRESSION”, (Grant Ref. PTDC/SAU-GMG/72168/2006). **2007-2010**. Funded by Portuguese Science & Technology Foundation. **BUDGET: € 150.000,00**
1. “IDENTIFICATION OF MOLECULAR MECHANISMS UNDERLYING GASTRIC CANCER IN POSITIVE AND NEGATIVE FAMILIES FOR GERMLINE CDH1 MUTATIONS”. (Grant Ref. POCI/SAU-OBS/58111/2004); **2005-2008**. Funded by Portuguese Science & Technology Foundation. **BUDGET: € 92.180,00**

Team Member (n=17 projects with a total budget of 2.9M€)

17. “DISCLOSING THE GENESIS OF HEREDITARY STOMACH CANCER THROUGH ORGAN-ON-A-CHIP TECHNOLOGY”. [DETONATE], (Project Ref: 2022.02951.PTDC), **2023-2024**. Portuguese Science & Technology Foundation. (PI: Daniel Ferreira, ERiC group, Ipatimup/i3S, Porto, Portugal)
16. “MISTRANSLATION: A NOVEL TRIGGER OF GENOME INSTABILITY IN CANCER”. [MISTiC], (Project Ref: PTDC/MED-ONC/28834/2017), **2018-2021**. Portuguese Science & Technology Foundation. (PI: Mafalda Santos, ERiC group, Ipatimup/i3S, Porto, Portugal)
15. "UNDERSTANDING THE IMPACT OF ACQUIRED AND GERMLINE GENETIC VARIANTS IN THE COMPLEXITY OF GASTRIC CANCER." (Project Ref: IF/01127/2014 to Pedro Ferreira), **2015-2020**. Portuguese Science & Technology Foundation. (PI: Pedro Ferreira, ERiC group, Ipatimup/i3S, Porto, Portugal)

14. "IMPROVING GASTRIC CANCER PATIENT STRATIFICATION TOWARDS PERSONALISED THERAPY". (Project Ref. iFCT2013/00615 to Gabriela M Almeida), **2014-2018**. Portuguese Science & Technology Foundation. (PI: Gabriela M Almeida, ERiC group, Ipatimup/i3S, Porto, Portugal)
13. "DETECÇÃO DE MUTAÇÕES EM SANGUE PERIFÉRICO". [MUSA], (Project number 38704), **2013-2015**. Portuguese Agency of Research and Innovation. (PI: Paulo Canedo – Ipatimup Diagnostics, Porto, Portugal)
12. "THE SINGLET OXYGEN STRATEGY (SO2S)". (Project number 316975), **2012-2016**. Marie Curie Initial Training Networks 2012 - European Union Seventh Framework Programme FP7-PEOPLE-2012-ITN. Research Group from Partner Organization hosting secondments from the project. (PI: Bruno Sarmiento - Inovapotek Pharmaceutical Research and Development, Porto, Portugal)
11. "ADHESION, DIFFERENTIATION AND INVASION: DIFFERENT PROCESSES, COMMON CADHERIN PLAYERS". (Project Ref. PTDC/SAU-GMG/120049/2010), **2012-2015**. Portuguese Science & Technology Foundation. (PI: Joana Paredes, Ipatimup/i3S, Porto, Portugal)
10. "TUMOUR SPECTRUM IN HEREDITARY DIFFUSE GASTRIC CANCER". (Project Ref. PTDC/SAU-ONC/110294/2009), **2011-2014**. Portuguese Science & Technology Foundation. (PI: Raquel Seruca, Ipatimup/i3S, Porto, Portugal)
9. "FUNCTIONAL GENOMICS OF RIBOSOME INFIDELITY PHENOTYPES ASSOCIATED TO HUMAN DISEASES". (Project Ref. PTDC/SAU-GMG/098850/2008), **2010-2013**. Portuguese Science & Technology Foundation.
8. "EXPLORING THE ROLE OF E-CADHERIN-HER INTERACTION IN THE SEARCH OF MOLECULAR BIOMARKERS FOR THE CLINICAL MANAGEMENT OF GASTRIC CANCER PATIENTS". (Project Ref. PIC/IC/82923/2007), **2009-2012**. Portuguese Science & Technology Foundation.
7. "IMPLEMENTATION OF A NATIONAL FACILITY FOR DNA MICROARRAYS: PHASE II". (Project Ref. PTDC/BIA-BCM/64745/2006), **2009-2011**. Portuguese Science & Technology Foundation.
6. "MLK3, A NEW MUTATED GENE IN MSI COLORECTAL CANCER". (Project Ref. PTDC/SAU-OB/68310/2006), **2008-2011**. Portuguese Science & Technology Foundation.
5. "PREVENTION, DETECTION AND MOLECULAR CHARACTERIZATION OF MISMATCH REPAIR-RELATED HEREDITARY CANCERS OF THE DIGESTIVE SYSTEM". (Project Ref. Contract LSCH/CT/2005/018754, MMR-related cancer), **2006-2009**. FP6, Program for research and technological development for specific targeted research project.
4. "IDENTIFICATION OF SIGNALING PATHWAYS INVOLVED IN CDX2 REGULATION IN TWO HUMAN MODELS OF ALTERED INTESTINAL DIFFERENTIATION: INTESTINAL METAPLASIA AND JUVENILE POLYPOSI". (Project Ref. POCI/SAU-OBS/55840/2004); **2005-2008**. Portuguese Science & Technology Foundation.
3. "IN MISMATCH REPAIR DEFICIENCY COLORECTAL CANCER ARE BRAF AND KRAS NEW PROGNOSTIC AND THERAPEUTIC TOOLS?". (Project Ref. POCI/SAU-OBS/56921/2004), **2005-2008**. Portuguese Science & Technology Foundation.
2. "MECHANISMS INTERFERING WITH CELLULAR INVASION AND APPLICATIONS IN ONCOLOGY AND PRE-NATAL DIAGNOSIS". (Project Ref. INV-ONC-DPN), **2005-2007**. Portuguese Agency of Research and Innovation.
1. "E-CADHERIN GERMLINE MUTATIONS AND HEREDITARY DIFFUSE GASTRIC CANCER: FUNCTIONAL, BIOCHEMICAL AND MOLECULAR CHARACTERIZATION". (Project Ref. POCTI/CBO/40820/2001), **2002-2005**. Portuguese Science & Technology Foundation.

---

## FUNDING FOR PERSONNEL

**Overall budget obtained for personnel so far ~ € 2.500.00,00** (based on Portuguese salary/fellowship scale). In total, Carla Oliveira's team has been successful in the application for **35 PhD, Post-doc or iFCT** proposals.

2022-2024	Portuguese Science & Technology Foundation: <b>One PhD Fellowships (2 years)</b>
2020-2024	Portuguese Science & Technology Foundation: <b>Two PhD Fellowships (4 years)</b>
2019-2023	Portuguese Science & Technology Foundation: <b>Two PhD Fellowships (4 years)</b>
2018-2022	Portuguese Science & Technology Foundation: <b>Four PhD Fellowships (4 years)</b>

- 2017-2021 Portuguese Science & Technology Foundation: **Three PhD Fellowships (4 years)**
- 2016-2020 BiotechHealth PhD Program/FCT: **One PhD Fellowship (4 years)**
- 2016-2020 Portuguese Science & Technology Foundation: **One PhD Fellowship (4 years)**
- 2015-2019 Portuguese Science & Technology Foundation: **One Investigator FCT contract (junior PI – 5 years)**
- 2014-2018 Portuguese Science & Technology Foundation: **One Investigator FCT contract (junior PI – 5 years)**
- 2014-2017 BiotechHealth PhD Program/FCT: **One PhD Fellowship (4 years)**
- 2013-2016 Portuguese Science & Technology Foundation: **Two PhD Fellowships (4 years)**
- 2013-2015 Portuguese Science & Technology Foundation: **Three Post-doc Fellowships (6 years)**
- 2011-2012 Portuguese Science & Technology Foundation: **One Sabbatical Fellowship to Carla Oliveira (1 year)**
- 2012-2015 Portuguese Science & Technology Foundation: **Three Post-doc scholarships (3 years)**
- 2009-2012 Portuguese Science & Technology Foundation: **Two Ph.D. scholarships (3 years)**
- 2008-2011 Portuguese Science & Technology Foundation: **One Ciência 2007 contract (4 years)**
- 2008-2011 Portuguese Science & Technology Foundation: **Two Ph.D. scholarships (3 years)**
- 2008-2011 EMBO short term fellowships: **Four fellowships for Ph.D. students (3 years)**
- 2005-2008 Portuguese Science & Technology Foundation: **Two Ph.D. scholarships (3 years)**
- 2005 EACR travel fellowship European Association for Cancer Research (EACR): **€2.000,00 (1 year)**

## SUPERVISION EXPERIENCE

### COMPLETED supervision of Students and Post-Doctoral fellows and Junior Researchers:

#### Post-Doctoral and Junior Researchers Supervision

	Student   Thesis title   Supervisor   Institution	Degree   Data graduation   Current position
1.	<p>Patricia Pereira in the frame of the project "FUNCTIONAL GENOMICS OF RIBOSOME INFIDELITY PHENOTYPES ASSOCIATED TO HUMAN DISEASES"). <b>Post-doc 1<sup>st</sup> January 2010 to 31<sup>st</sup> December 2012.</b></p> <p>Gabriela Almeida "TARGETING CHEMOTHERAPY-INDUCED EMT AND CANCER STEM CELLS FOR OVERCOMING TUMOUR DRUG RESISTANCE" (Ref. SFRH/BPD/87257/2012). <b>Post-doc 1<sup>st</sup> April 2013 to 31<sup>st</sup> December 2013.</b></p>	<p><b>Currently</b> a Medical Doctor finalizing the specialization in Medical Oncology, Lisbon, PT.</p>
2.	<p>Gabriela Almeida in the frame of the project "IMPROVING GASTRIC CANCER PATIENT STRATIFICATION TOWARDS PERSONALISED THERAPY". Research Associate with an iFCT contract for 5 years (Project Ref. iFCT2013/00615). <b>Contract 1<sup>st</sup> January 2014 to 31<sup>st</sup> December 2018.</b></p> <p>Gabriela Almeida "SOLVING THE 3D CHROMATIN STRUCTURE OF CDH1 LOCUS TO IDENTIFY DISEASE-ASSOCIATED MECHANISMS" (Ref. POCI-01-0145-FEDER-030164). <b>Junior Researcher contract 1<sup>st</sup> January 2019 30<sup>th</sup> April 2021.</b></p>	<p><b>Currently</b> Data Protection Office Manager at i3S, Porto, PT.</p>
3.	<p>Denisa Mateus in the frame of the project "NEW E-CADHERIN RNAs: THE DARK SIDE OF A TUMOUR SUPPRESSOR GENE" (Ref. PTDC/SAU-</p>	<p><b>Currently</b> a Post-doc at the Centre of Neurosciences, Coimbra, PT.</p>



GMG/110785/2009). **Post-doc 1<sup>st</sup> September to 31<sup>st</sup> March 2013.**

Hugo Pinheiro "CDH1 LOCUS, THE NEXT JEKYLL AND HYDE IN CANCER?" (Ref. SFRH/BPD/79499/2011 1<sup>st</sup> Trienium). **Post-doc 1<sup>st</sup> January 2012 to 31<sup>st</sup> December 2014.**

4. Hugo Pinheiro "CDH1 EXPRESSION REGULATION: AN ALTERNATIVE MOLECULAR CAUSE FOR HEREDITARY DIFFUSE GASTRIC CANCER" (Ref. SFRH/BPD/79499/2011 - 2<sup>nd</sup> Trienium). **Post-doc 1<sup>st</sup> January 2015 to 31<sup>st</sup> December 2016.**

**Currently** a Medical Doctor completing the Specialization in Internal Medicine and a Consultant in my group at IPATIMUP/i3S, Porto, PT.

5. Ana Sofia Ribeiro "ADHESION, DIFFERENTIATION AND INVASION: DIFFERENT PROCESSES, COMMON CADHERIN PLAYERS". (Ref. PTDC/SAU-GMG/120049/2010). Co-supervision by Carla Oliveira ERiC Group, Ipatimup/i3S.). **Post-doc 1<sup>st</sup> January 2012 to 31<sup>st</sup> December 2016.**

**Currently** a Junior Researcher at the EPIC Group (Raquel Seruca's Lab) at i3S, Porto, PT.

Patricia Oliveira "ALL TOGETHER NOW: COMBINED INFLUENCE OF E-CADHERIN MODULATORS IN EPITHELIAL-MESENCHYMAL-EPITHELIAL TRANSITIONS AND CANCER PROGRESSION" (Ref. SFRH/BPD/89764/2012 – 1<sup>st</sup> Trienium). **Post-doc 1<sup>st</sup> January 2013 to 31<sup>st</sup> December 2015.**

6. Patrícia Oliveira "EMT/MET IN GASTRIC CANCER: USING NEXT GENERATION SEQUENCING DATA TO UNCOVER NOVEL THERAPEUTIC TARGETS" (Ref. SFRH/BPD/89764/2012 - 2<sup>nd</sup> Triennium). **Post-doc 1<sup>st</sup> January 2016 to 31<sup>st</sup> December 2018.**

**Currently** a Junior Researcher at Ipatimup Diagnostics, Porto, PT.

Joana Carvalho "STUDY OF SECRETED CELL VESICLES DURING EPITHELIAL-MESENCHYMAL-EPITHELIAL TRANSITIONS AND THEIR ROLE IN THE CANCER METASTATIC PROCESS" (Ref. SFRH/BPD/86543/2012 – 1<sup>st</sup> Trienium). **Post-doc 1<sup>st</sup> March to 31<sup>st</sup> July 2013.**

7. Joana Carvalho "CIRCULATING EXOSOMES: A TOOL TO FOLLOW GASTRIC TUMOUR DYNAMICS AND THERAPY RESPONSE" (Ref. SFRH/BPD/86543/2012 - 2<sup>nd</sup> Triennium). **Post-doc 1<sup>st</sup> August to 31<sup>st</sup> December 2018.**

**Currently** a Junior Researcher at the EPIC Group (Raquel Seruca's Lab) at i3S, Porto, PT.

8. Sílvia Bidarra "ARTIFICIAL EXTRACELLULAR MATRIX-LIKE MATRICES AS 3D IN VITRO MODELS TO INVESTIGATE THE ROLE OF THE MICROENVIRONMENT IN CANCER METASTASISATION" (Ref. SFRH/BPD/80571/2011 - 2<sup>nd</sup> Triennium). Collaboration with Cristina Barrias, INEB, Porto PT (Co-supervision). **Post-doc 1<sup>st</sup> April 2016 to 30<sup>th</sup> November 2018.**

**Currently** a Junior Researcher at the Bioengineered 3D Microenvironments Group at i3S, Porto, PT.

9. Anabela Ferro "DISSECTING THE 3D CHROMATIN ARCHITECTURE OF THE CDH1 LOCUS" (Ref. NORTE/01/0145/FEDER/000029). **Post-doc 1<sup>st</sup> March 2014 to 31<sup>st</sup> December 2018.**

**Currently** a Junior Researcher at Ipatimup Diagnostics, Porto, PT.

10. Mafalda Santos "TRANSLATION ERRORS: A NEW INSTIGATOR OF GENOMIC INSTABILITY IN CANCER" (Ref. POCI-01-0145-FEDER-028834). **Junior**

**Currently** a Science Communication Manager at Lyris, Lisboa, PT.

**Researcher contract 1<sup>st</sup> December 2018 to 28<sup>th</sup> February 2022.**

**Ph.D. Supervision**

Student   Thesis title   Supervisor   Institution	Degree   Data graduation   Current position
1. Rachid Karam "THE ROLE OF NONSENSE-MEDIATED MRNA DECAY (NMD) IN THE REGULATION OF CDH1 GENE EXPRESSION AND CANCER DEVELOPMENT", FMUP, Univ. Porto, Portugal. <b>PhD student 1<sup>st</sup> January 2005 to 2<sup>nd</sup> December 2008.</b>	<b>Currently</b> Director, Ambry Translational Genomics (ATG) Lab, San Diego, California, USA.
2. Sónia Melo "EPIGENETIC, GENETIC AND FUNCTIONAL ANALYSES OF MICRORNA-MACHINERY IN HUMAN CANCER", FMUP, Univ. Porto, Portugal. Co-supervision by Carla Oliveira ERIC Group, Ipatimup/i3S. <b>PhD student 1<sup>st</sup> January 2006 to 13<sup>th</sup> April 2010.</b>	<b>Currently</b> a Research Associate with an iFCT contract for 5 years (Project Ref. iF/00543/2013).
3. S�rgia Velho "THE ROLE OF BRAF AND KRAS ACTIVATING MUTATIONS IN DEFICIENT AND PROFICIENT MMR COLORECTAL CARCINOMAS", FMUP, Univ. Porto, Portugal. Co-supervision by Carla Oliveira ERIC Group, Ipatimup/i3S. <b>PhD student 1<sup>st</sup> January 2006 to 31<sup>st</sup> May 2010.</b>	<b>Currently</b> a Junior Researcher at the EPIC Group (Raquel Seruca's Lab) at i3S, Porto, PT.
4. Hugo Pinheiro "E-CADHERIN: NEW REGULATORY MECHANISMS IN CANCER", FMUP, Univ. Porto, Portugal. <b>PhD student 1<sup>st</sup> March 2008 to 22<sup>th</sup> December 2011.</b>	<b>Currently</b> a Medical Doctor completing the Specialization in Internal Medicine and a Consultant in my group at IPATIMUP/i3S, Porto, PT.
5. Patricia Oliveira "IDENTIFICATION OF NOVEL CIS-REGULATORY ELEMENTS IN THE CADHERIN SUPERFAMILY AND CHARACTERIZATION OF THEIR ROLE IN CANCER-RELATED PROCESSES", ICBAS, Univ. Porto, Portugal. <b>PhD student 1<sup>st</sup> January 2007 to 31<sup>st</sup> December 2010.</b>	<b>Currently</b> a Junior Researcher at Ipatimup Diagnostics, Porto, PT.
6. Joana Carvalho on "THE INVOLVEMENT OF MICRORNAS IN GASTRIC CANCER", FMUP, Univ. Porto, Portugal. <b>PhD student 1<sup>st</sup> January to 7 December 2012.</b>	<b>Currently</b> a Junior Researcher at the EPIC Group (Raquel Seruca's Lab) at i3S, Porto, PT.
7. Renata Bordeira-Carriço on "SUPPRESSOR-TRNAS AS THERAPEUTIC TOOLS FOR CANCER ASSOCIATED SYNDROMES: HDGC AS A MODEL SYSTEM", FMUP, Univ. Porto, Portugal. <b>PhD student 1<sup>st</sup> February 2009 to 18 March 2013.</b>	<b>Currently</b> a Medical student, University of Lisbon, Lisbon, PT.
8. Ana Sofia Varanda "UNRAVELLING THE CELLULAR NETWORKS THAT REGULATE PROTEOTOXIC STRESS" (Ref. SFRH/BD/76417/2011). <b>PhD student 1<sup>st</sup> February 2012 to 27<sup>th</sup> March 2017.</b>	<b>Currently</b> a Post-doc at the Center for Neuroscience and Cell Biology, Coimbra, PT.
9. Patrick Kennedy "INNOVATIVE COLORECTAL CANCER DIAGNOSIS AND TREATMENT WITH ENGINEERED NANOPARTICLES" (Ref. SFRH/BD/99036/2013). Collaboration with Bruno O-Sarmento and Pedro Granja, INEB, Univ. Porto, Portugal. <b>PhD student 1<sup>st</sup> January 2014 to 11<sup>th</sup> July 2018.</b>	<b>Currently</b> a Senior Researcher at the company Phyzat Biopharmaceuticals, Porto, PT.

10. Mafalda Santos "UNRAVELLING THE ROLES OF STATISTICAL PROTEOMES IN HUMAN CANCER" (Ref. SFRH/BD/91020/2012). (Co-supervision). **PhD student 1<sup>st</sup> February 2013 to 16<sup>th</sup> February 2018.** **Currently** a Science Communication Manager at Lyris, Lisboa, PT.
11. Irene Gullo "MORPHOLOGICAL AND IMMUNOPHENOTYPIC HETEROGENEITY IN GASTRIC CANCER". (2013-2016). (Co-supervision). Collaboration with Fátima Carneiro, FMUP, Univ. Porto, Porto PT. **PhD student 1<sup>st</sup> September 2013 to 11<sup>th</sup> March 2019.** **Currently** a Medical Doctor completing the Specialization and a Consultant in my group at IPATIMUP/i3S, Porto, PT.
12. Bianca Lourenço "BIOENGINEERING 3D MODELS TO DECONSTRUCT THE ROLE OF EXTRACELLULAR MATRIX MICROENVIRONMENT IN GASTRIC CANCER" (Ref. SFRH/BD/87400/2012). (Co-supervision). Collaboration with Pedro Granja, INEB, Univ. Porto, Porto PT. **PhD student 1<sup>st</sup> January 2013 to 6<sup>th</sup> September 2019.** **Currently** a Regulatory Affairs - Medical Devices at i3S, Porto, PT.
13. Sara Rocha "DECONSTRUCTING GASTRIC CANCER COLONIZATION: THE INTERPLAY BETWEEN IMMUNE CELLS, GASTRIC CANCER CELLS AND EXTRACELLULAR VESICLES" (BiotechHealth PhD Program/FCT Ref. PD/BD/128406/2017). Collaboration with João Barata IMM, Lisbon, PT; Marta Oliveira, INL, Braga, PT and Joana Carvalho, ERiC, Ipatimup/i3S. **PhD student 1<sup>st</sup> January 2017 to 17<sup>th</sup> July 2020.** **Currently** a Science Writer in iLoF - Intelligent Lab on Fiber, UK.
14. Carla Pereira "UNVEILING THE CROSSTALK BETWEEN E-CADHERIN AND CD44-SPLICE VARIANTS AS A NOVEL STRATEGY TO IMPROVE DRUG SENSITIVITY IN GASTRIC CANCER" (Ref. SFRH/BD/113031/2015). Co-supervised by Gabriela Almeida, ERiC group, Ipatimup/i3S. **PhD student 1<sup>st</sup> December 2015 to 12<sup>th</sup> November 2020.** **Currently** Project Manager at Genbet Biopharmaceuticals, Oeiras, PT.
15. Daniel Ferreira "A TISSUE ENGINEERING APPROACH TO BUILDING A STOMACH-ON-A-CHIP" (Ref. PD/BD/105976/2014). (Co-supervision). Collaboration with Pedro Granja, INEB, Univ. Porto, Porto PT. **PhD student 1<sup>st</sup> July 2014 to 14<sup>th</sup> December 2021.** **Currently** Junior Researcher in my group at IPATIMUP/i3S, Porto, PT
16. Abel Sousa "STUDY OF CONTROL OF PROTEIN ABUNDANCE USING MULTI-OMICS DATA FROM CANCER SAMPLES". GABBA Program (Ref. PD/BD/128007/2016). (Co-supervision). Collaboration with Pedro Beltrão EMBL-EBI, Cambridge, UK and Pedro Ferreira, ERiC, Ipatimup/i3S. **PhD student 1<sup>st</sup> in January 2017 to 7<sup>th</sup> October 2021.** **Currently** Senior Data Scientist at AstraZeneca Cambridge, England, UK

### Master's Thesis Supervision

- | Student   Thesis title   Supervisor   Institution  | Degree   Data graduation   Current position   |
|--|---|
| 1. Hugo Pinheiro "E-CADHERIN SILENCING: MORE THAN INACTIVATING MUTATIONS". Univ. Minho, Braga, Portugal. <b>MSc. Graduated in December 2007.</b> | <b>Currently</b> a Medical Doctor completing the Specialization in Internal Medicine and a Consultant in my group at IPATIMUP/i3S, Porto, PT. |

2. Pedro Freitas, "EXPRESSION ANALYSIS OF MICRORNAS TARGETING ADHESION COMPLEX MOLECULES IN GASTRIC CANCER". Integrated Masters in Medicine, FMUP, Univ. Porto, Portugal. **MSc. Graduated in June 2012.**  
**Currently** a Medical Doctor at the Centro Hospitalar de Lisboa Ocidental, E.P.E, Lisbon, PT.
3. Mafalda Azevedo "AN IN VITRO MODEL OF EMT/MET USING HUMAN NEAR-NORMAL AND CANCER-DERIVED BREAST CELL LINES". ICBAS, Univ. Porto, Portugal. **MSc. Graduated in December 2012.**  
**Currently** a GABBA PhD Program student, New York, USA.
4. Inês Reis "DIES1 GENE EXPRESSION AND REGULATION IN GASTRIC CANCER". ICBAS, Univ. Porto, Portugal. **MSc. Graduated in November 2014.**  
**Currently** Head Technician at the Neuropathology Dept. at Hospital Geral Santo António, Porto PT.
5. Pedro Queirós "KRAS MUTATIONS IN MICROSATELLITE INSTABLE GASTRIC TUMOURS: IMPACT OF TARGETED TREATMENT AND INTRATUMOURAL HETEROGENEITY". Integrated Masters in Medicine FMUP, Univ. Porto, Portugal. **MSc. Graduated in June 2015.**  
**Currently** a Medical Doctor at the Centro Hospitalar Vila Nova de Gaia/Espinho, E.P.E., Porto, PT.
6. Hugo Pinheiro "HEREDITARY DIFFUSE GASTRIC CANCER BEYOND *CDH1* CODING MUTATIONS". Univ. Minho, Braga, Portugal. Integrated Masters in Medicine, Univ. Minho, Portugal. **MSc. Graduated in January 2016.**  
**Currently** a Medical Doctor completing the Specialization in Internal Medicine and a Consultant in my group at IPATIMUP/i3S, Porto, PT.
7. Ana Aguiar "CHARACTERIZATION OF AN E-CADHERIN-RELATED COMMON ANCESTOR IN HEREDITARY DIFFUSE GASTRIC CANCER FAMILIES FROM THE NORTHERN PORTUGAL". Integrated Masters in Medicine, FMUP, Univ. Porto, Portugal. **MSc. Graduated in July 2016.**  
**Currently** a Medical Doctor completing the Specialization in Clinical Pathology and a Consultant in my group at IPATIMUP/i3S, Porto, PT.
8. Ana Sofia Valente "CDH1 REGULATORY VARIANTS AND HEREDITARY DIFFUSE GASTRIC CANCER". Univ. Porto, Portugal. Masters in Molecular and Cellular Biology, FCUP, Univ. Porto, Portugal. **MSc. Graduated in November 2016.**  
**Currently** a Researcher in the Company Fairjourney Biologics, Porto, PT.
9. Celina Beatriz Teixeira São José "THE GERMLINE AND SOMATIC LANDSCAPE OF FAMILIAL INTESTINAL GASTRIC CANCER: SEARCH FOR A CAUSE". Master in Oncology, ICBAS, Univ. Porto, Portugal. **MSc. Graduated in November 2017.**  
**Currently** a PhD student in my group at IPATIMUP/i3S, Porto, PT in collaboration with Stefan Mundlos, Max Planck Institute in Berlin, DE.
10. Rafaela Silva "CLINICAL AND FUNCTIONAL IMPACT OF A CDH1 GENE MUTATION: FROM THE DEFINITION OF A COMMON ANCESTOR TO THE FUNCTIONAL CHARACTERIZATION OF A CAUSATIVE MUTATION". Master in Medical and Molecular Oncology, FMUP, Univ. Porto, Porto PT. **MSc. Graduated in September 2018.**  
**Currently** Molecular Biology Technician in Klinikum Rechts der Isar der Technischen Universität München, DE.
11. Sara Teles "DISCLOSING HYPOMETHYLATION AS AN ONCOGENE ACTIVATION MECHANISM". Master in Oncology, ICBAS, Univ. Porto, PT. **MSc. Graduated in October 2018.**  
**Currently** a Research Assistant in Cancer Researcher Cambridge Institute, UK.
12. Ana Rita Matos "CDH1 GENOMIC BLUEPRINT: THE ROLE OF ITS CIS-REGULATORY ELEMENTS". Master in Medical and Molecular Oncology, FMUP, Univ. Porto, Portugal. **MSc. Graduated in November 2018.**  
**Currently** a PhD student in my group at IPATIMUP/i3S, Porto, PT in collaboration with

Porto, Porto PT. **MSc. Graduated in November 2018.** Gustavo Mostoslavsky, Center for Regenerative Medicine (CReM) Boston, USA.

13. Silvana Sousa "BIOMARKERS IN GASTRIC CANCER". Master in Oncology, ICBAS, Univ. Porto, PT. **MSc. Graduated in October 2019.** **Currently** a PhD student in my group at IPATIMUP/i3S, Porto, PT

14. Francisco Almeida "ANALYSIS AND COMPARISON TOOL FOR MULTIPLE VARIANT CALLING RESULTS FROM GERMLINE NGS DATA WITH CLINICAL APPLICATIONS". Master in Bioinformatics and Computational Biology, FCUP, Univ. Porto, PT. **MSc. Graduated in 17 December 2021.** **Currently** Bioinformatician, Group affiliated member in my group at IPATIMUP/i3S, Porto, PT

15. Sérgio Marinho "tRNA-Ser-AGA: A NEW PLAYER IN NSCLC CISPLATIN RESISTANCE". Master in Medicine and Molecular Oncology, FMUP, Univ. Porto, PT. **MSc. Graduated in December 2021.** **Currently** a Research Technician in i3S, Porto, PT

#### **PAST Foreign Students Supervision**

1. Barbara Korsak "EVALUATION OF IN VIVO EFFICACY OF HER2 TARGETED PHOTOIMMUNOTHERAPY OF GASTRIC CANCER". PhD Secondment in the frame of a Marie Curie Initial Training Networks 2012 - FP7-PEOPLE-2012-ITN. 18 months Secondment under the supervision of Carla Oliveira (**2014-2015**).
2. Richa Kandhuri "CHARACTERIZATION OF EXOSOMES DERIVED FROM BREAST CANCER AND GASTRIC CANCER CELLS CULTURED IN 2D VERSUS 3D ENVIRONMENTS". PhD Program at Faculty of Medicine, University of Freiburg, Freiburg, Germany. One month internship under the supervision of Carla Oliveira (**Feb 2016**).
3. Andrea R. B. Carpinteyro "ANALYSIS OF MUTATION, METHYLATION STATUS AND EXPRESSION OF THE CDH1 GENE IN MEXICAN PATIENTS WITH DIFFUSE GASTRIC CANCER". PhD Program at Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Mexico. Four-month internship under the supervision of Carla Oliveira (**Jun-Sept 2016**).
4. Mónica Martiñez Fernández "DEVELOPMENT OF COMPUTATIONAL METHODS FOR THE ANALYSIS OF HIGH-THROUGHPUT GENOMICS DATA FROM BLADDER CANCER". Programa "José Castillejo" para estancias de movilidad en el extranjero de jóvenes doctors under the supervision of Carla Oliveira and Pedro Ferreira (**Aug-Oct 2016**).
5. Fernanda Murani "MUTATIONAL PROFILE OF OESOPHAGEAL CANCER WITH OR WITHOUT CHAGAS MEGA-OEASOPHAGUS IN BRASILIEN PATIENTS". Master student, Barretos Cancer Hospital, Brazil. Three months internship under the supervision of Pedro Ferreira (**May-July 2017**).
6. Gianluca Tedaldi "IDENTIFICATION OF NEW MOLECULAR FACTORS INVOLVED IN THE DEVELOPMENT OF FAMILIAL GASTRIC CANCERS". PhD Program at Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) Srl – IRCCS, Meldola, Italy. Six months internship under the supervision of Carla Oliveira (**Jan-July 2018**).
7. Uma Thanigai Arasu "INVESTIGATING THE EPITHELIAL TO MESENCHYMAL TRANSITION (EMT) USING 3D IN VITRO MICROARRAY MODEL". Master Program at Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland. One month internship under the supervision of Carla Oliveira (**Mar 2018**).
8. Etienne Rolland "DEVELOPMENT OF BIOINFORMATICS TOOLS TO EXPLORE AND COMPARE CELLULAR AND EV-CONTENTS" (Ref. H2020/MSCA/ITN/2016). Co-supervised by Pedro Ferreira, ERiC group, Ipatimup/i3S. (**May 2018-Feb 2019**).
9. Ji-Hyeon Park, "THE ROLE OF CD44V6 OVEREXPRESSION AND E-CADHERIN IMPAIRMENT IN GASTRIC CANCER." Visiting Gastric Surgeon, Seoul National University Hospital & Seoul National University College of Medicine. (**September 2019**).

**ONGOING Supervision** of Students and Post-Doctoral fellows:

### Post-Doctoral Supervision

1. Ana André "ADVANCING CANCER RESEARCH: FROM BASIC KNOWLEDGE TO APPLICATION" (Ref. NORTE-01-0145-FEDER-000029). **Post-doc started in November 2017.**
2. Tiago Santos "TISSUE ENGINEERED 3D MODELS OF GASTRIC WALL FOR PERMEABILITY STUDIES OF DRUG LOADED NANOPARTICLES" (Ref. SFRH/BPD/103113/2014 -2<sup>nd</sup> Triennium). Collaboration with Pedro Granja and Bruno Sarmiento, INEB, Univ. Porto, Porto PT (Co-supervision). **Post-doc started in February 2018.**

### Ph.D. THESIS SUPERVISION

1. Rúben Rodrigues "DEVELOPMENT OF AN INTEGRATED KNOWLEDGE BASE FOR GASTRIC CANCER" (FCT Ref: SFRH/BD/131916/2017). (Co-supervision). Collaboration with Miguel Rocha, University of Minho, Braga, PT. **PhD started in September 2017.**
2. Celina São José "UNVEIL CDH1 REGULATORY NETWORK, BEYOND CODING MUTATIONS IN HDGC" (FCT Ref. SFRH/BD/140796/2018). Collaboration with Stefan Mundlos, Max Planck Institute, Berlin, DE. **PhD fellowship funded. PhD started in October 2018.**
3. José Peláez "SOLVING THE UNSOLVED RARE DISEASES: HEREDITARY DIFFUSE GASTRIC CANCER" (Project Ref. reference H2020-SC1-2017-Single-Stage-RTD). Collaboration with Nicoline Hoogerbrugge from Radboud University Medical Center of Nijmegen, NL and Marc Tischkowitz from the University of Cambridge, UK. **PhD fellowship funded. PhD started in October 2018.**
4. Joana Guerra "INHERITED PREDISPOSITION TO GASTRIC CANCER: NOVEL SUSCEPTIBILITY GENES AND A MINIMALLY INVASIVE SCREENING STRATEGY IN GERMLINE MUTATION CARRIERS" (FCT Ref. SFRH/BD/138670/2018). (Co-supervision). Collaboration with Manuel Teixeira, ICBAS/IPO Porto, Porto, PT. **PhD fellowship funded. PhD started in January 2019.**
5. Ana Rita Matos "THE PRIMARY GENETIC CAUSE AND BEYOND: LIFE-TIME RISK AND PHENOTYPE MODIFIERS IN HDGC" (FCT Ref. SFRH/BD/145132/2019). Co-supervised by Gustavo Mostoslavsky, Center for Regenerative Medicine (CReM) Boston, USA. **PhD fellowship funded. PhD started in October 2019.**
6. Liliana Sousa "RARE CANCER ASSOCIATED SYNDROMES: THE IMPACT OF APPROPRIATE PATHWAYS OF CARE ON HEALTH ECONOMICS AND DISEASE PREVENTION" (FCT Ref. SFRH/BD/144911/2019). Collaboration with Ana Carvalho, EEG-UMinho Braga, PT. **PhD fellowship funded. PhD started in January 2020.**
7. Silvana Lobo "DEVELOPMENT OF AN ALGORITHM FOR CLASSIFICATION OF VARIANTS OF UNKNOWN SIGNIFICANCE (VUS) USING A COMBINATION OF IN SILICO, IN VITRO AND IN VIVO STUDY MODELS" (FCT Ref. 2020.05773.BD). Co-supervised by Paulo Pereira, IBMC/i3S and Patrick Benusiglio, Faculté de Médecine, Sorbonne Université and Hôpitaux Universitaires Pitié Salpêtrière, Département de Génétique, Unité Fonctionnelle d'Oncogénétique. **PhD fellowship funded. PhD started in February 2021.**
8. Marta Ferreira "BIOPREDICTOR: A TOOL TO PREDICT THE OUTCOME OF MOLECULAR ALTERATIONS." (FCT Ref. 2020.05763.BD). Co-supervised by Pedro Ferreira, Department of Computer Science, Faculty of Sciences of the University of Porto. **PhD fellowship funded. PhD started in May 2021.**
9. José Peláez "A WORLDWIDE APPROACH TO IMPROVE MANAGEMENT FOR FAMILIES WITH HEREDITARY DIFFUSE GASTRIC CANCER (HDGC)" (FCT Ref. 2022.11952.BD). **PhD fellowship funded. PhD started in January 2023.**

### MSc THESIS SUPERVISION

1. André Pinto Oliveira "THE IMPACT OF NONSENSE MEDIATED DECAY ON CTNNA1 VARIANTS IN TUMORIGENESIS AND DIFFERENTIATION". Master Program in Bioengineering, FEUP/ICBAS, Univ. of Porto. **MSc. started in October 2021.**
2. Inês Marques "DEVELOPMENT OF METHODS AND PIPELINES FOR NGS DATA ANALYSIS". Master Program in Bioinformatics and Computational Biology, FCUP, Univ. of Porto. **MSc started in February 2022.**
3. Nelson Martins "IMPACT OF SOMATIC LOSS OF CDH1 LOCUS AND/OR 16Q ARM IN BREAST CANCER PROGRESSION" Master Program in Medicine and Molecular Oncology, Faculty of Medicine, Univ. of Porto. **MSc started in March 2022.**

### Supervision of other Researchers

- Oct, 2017-  
Apr, 2021 Marta Ferreira “*LABORATÓRIO NACIONAL DE SEQUENCIAÇÃO E ANÁLISE DE GENOMAS*”. **Research Technician** (Ref: POCI-01-0145-FEDER-02218). IPATIMUP/i3S, Porto, PT.
- Oct, 2017-  
Dec, 2018 Barbara Mesquita “*MAPPING GENETIC AND PHENOTYPIC HETEROGENEITY IN HER2 POSITIVE CANCERS TO ANTICIPATE AND COUNTERACT RESISTANCE PHENOTYPES*”. **Research Fellowship – MSc** (Ref: NORTE-01-0145-FEDER-000029). IPATIMUP/i3S, Porto, Pt.
- Jul, 2018-  
Aug, 2019 Sara Teles “*3DEMT - UMA PLATAFORMA DE MICROARRAYS EM 3D PARA A ANÁLISE DE ALTO RENDIMENTO DO PAPEL DA MATRIZ EXTRACELULAR NAS TRANSIÇÕES EPITELIAL-MESENQUIMAL EM CANCRO*”. **Research Fellowship – BI-L** (Ref: PTDC/BBB-ECT/2518/2014). IPATIMUP/i3S, Porto, Pt.
- Jul, 2018-  
Sept, 2019 Liliana Sousa “*ADVANCING CANCER RESEARCH: FROM BASIC KNOWLEDGE TO APPLICATION*”. **Research Fellowship – MSc** (Ref: NORTE-01-0145-FEDER-000029). IPATIMUP/i3S, Porto, Pt.
- Jan, 2019 -  
July, 2019 Marta Moreno “*IntCDH1 – THE INTRONIC REGULATION OF THE CDH1 GENE*”. **Research Fellowship – MSc** (Ref: IntCDH1). IPATIMUP/i3S, Porto, Pt.
- Jan, 2019 –  
Sept, 2019 Ana Rita Matos “*3DEMT - UMA PLATAFORMA DE MICROARRAYS EM 3D PARA A ANÁLISE DE ALTO RENDIMENTO DO PAPEL DA MATRIZ EXTRACELULAR NAS TRANSIÇÕES EPITELIAL-MESENQUIMAL EM CANCRO*”. **Research Fellowship – MSc** (Ref: PTDC/BBB-ECT/2518/2014). IPATIMUP/i3S, Porto, PT.
- Fev, 2019 –  
July, 2020 Ana Rita Monteiro “*TACKLING CANCER STEM CELLS: A CHALLENGE AND AN OPPORTUNITY TO ADVANCE IN ANTI-CANCER THERAPY*”. **Research Fellowship – MSc** (Ref: POCI-01-0145-FEDER-016390). IPATIMUP/i3S, Porto, Pt.

### Summary of Under-graduate Students PAST Supervision

1. Degree Training supervision of Sara Teles, Univ. Porto, Portugal. Graduated in 2016
2. Degree Training supervision of Mafalda Azevedo, Univ. Aveiro, Portugal. Graduated in 2011
3. Degree Training supervision of Catarina Salgado, Univ. Porto, Portugal. Graduated in 2010
4. Degree Training supervision of Patrícia Inácio, Univ. Porto, Portugal. Graduated in 2007
5. Degree Training supervision of Sónia Melo, Univ. Porto, Portugal. Graduated in 2005
6. Degree Training Supervision of Sérgia Velho, Univ. Porto, Portugal. Graduated in 2004

---

### THESIS COMMITTEES AND JURY (Examiner=29; Jury member=35)

- 2022 Member of the Ph.D. Dissertation Committee Of Joana Teixeira, ICBAS, Portugal
- 2022 Invited Jury member (**examiner**): Ph.D. Thesis of Miguel Silva, ICBAS, Portugal
- 2021 Invited Jury member (**examiner**): Ph.D. Thesis of Joana Maia, ICBAS, Portugal
- 2021 Invited Jury member (**examiner**): Masters Dissertation of Ana Abreu, Univ. Aveiro, Portugal
- 2021 Member of the Masters Dissertation Committee of Francisco Almeida, FCUP, Portugal
- 2021 Member of the Ph.D. Dissertation Committee of Daniel Ferreira, ICBAS, Portugal
- 2021 Member of the Ph.D. Dissertation Committee of Abel Sousa, FCUP, Portugal
- 2020 Member of the Ph.D. Dissertation Committee of Carla Pereira, FMUP, Portugal
- 2020 Member of the Ph.D. Dissertation Committee of Sara Rocha, ICBAS, Portugal
- 2019 Invited Jury member (**examiner**): Ph.D. Thesis of Bianca Lourenço, FEUP, Portugal
- 2019 Invited Jury member (**examiner**): Ph.D. Thesis of Mafalda Matos, FMUL, Portugal
- 2018 Invited Jury member (**examiner**): Ph.D. Thesis of Ricardo Pais, IGC, Portugal
- 2018 Invited Jury member (**examiner**): Masters Dissertation of Diogo Ribeiro, Univ. Porto, Portugal

2018 Member of the Masters Dissertation Committee of Ana Rita Matos, Univ. Porto, Portugal

2018 Member of the Masters Dissertation Committee of Sara Teles, Univ. Porto, Portugal

2018 Member of the Ph.D. Dissertation Committee of Joana Nunes. Univ. Porto, Portugal

2018 Member of the Masters Dissertation Committee of Rafaela Silva, Univ. Porto, Portugal

2018 Invited Jury member (**examiner**): Masters Dissertation of Bárbara Alves. Univ. Porto, Portugal

2018 Invited Jury member (**examiner**): Ph.D. Thesis of Joana Lima. Univ. Porto, Portugal

2017 Invited Jury member (**examiner**): Masters Dissertation of Ricardo Cunha. Univ. Porto, Portugal

2017 Member of the Masters Dissertation Committee of Celina São José. Univ. Porto, Portugal

2017 Invited Jury member (**examiner**): Ph.D. Dissertation of Ana Metelo. Univ. Coimbra, Portugal

2017 Invited Jury member (**Pre-examiner**): Ph.D. Thesis of Elisa Lazaro Ibanez. Univ. Helsinki

2017 Member of the Ph.D. Dissertation Committee of Ana Sofia Varanda. Univ. Aveiro, Portugal

2016 Member of the Masters Dissertation Committee of Ana Aguiar. Univ. Porto, Portugal

2016 Invited Jury member (**examiner**): Ph.D. Dissertation of Suellen Ferro. Univ. Porto, Portugal

2015 Invited Jury member (**examiner**): Masters Dissertation of Diana Pinto. Univ. Porto, Portugal

2015 Invited Jury member (**examiner**): Masters Dissertation of Rita Faria. Univ. Porto, Portugal

2015 Member of the Ph.D. Dissertation Committee of Bruno Albuquerque. Univ. Porto, Portugal

2015 Member of the Ph.D. Dissertation Committee of João Curado e Silva. Univ. Porto, Portugal

2015 Member of the Ph.D. Dissertation Committee of Joana Santos. Univ. Porto, Portugal

2015 Member of the Masters Dissertation Committee of Pedro Queirós. Univ. Porto, Portugal

2015 Member of the Ph.D. Dissertation Committee of Margherita Francescato. Univ. Porto, Portugal

2014 Member of the Ph.D. Dissertation Committee of Germana Domingues. Univ. Lisbon, Portugal

2014 Invited Jury member (**examiner**): Ph.D. Dissertation of Joana Costa. Univ. Lisbon, Portugal

2014 Member of the Ph.D. Dissertation Committee of Irina Amorim. Univ. Porto, Portugal

2014 Invited Jury member (**examiner**): Masters Dissertation of João Coentro. Univ. Porto, Portugal

2014 Member of the Masters Dissertation Committee of Inês Reis. Univ. Porto, Portugal

2014 Invited Jury member (**examiner**): Masters Dissertation of Rui Barranha. Univ. Porto, Portugal

2014 Invited Jury member (**examiner**): Ph.D. Dissertation of Ana Ramos. Univ. Coimbra, Portugal

2013 Member of the Ph.D. Dissertation Committee of Bruno Pereira. Univ. Porto, Portugal

2013 Invited Jury member (**examiner**): Ph.D. Dissertation of Pedro Costa. Univ. Coimbra, Portugal

2013 Member of the Ph.D. Dissertation Committee of Renata Bordeira-Carriço. Univ. Porto, Portugal

2013 Invited Jury member (**examiner**): Ph.D. Dissertation of Cristovão Sousa. L'Université Pierre et Marie Curie. Paris, France

2012 Member of the Ph.D. Dissertation Committee of Joana Carvalho. Univ. Porto, Portugal

2012 Invited Jury member (**examiner**): Masters Dissertation of Diana Sobral Mesquita. Univ. Porto, Portugal

2012 Member of the Masters Dissertation Committee of Mafalda Azevedo. Univ. Porto, Portugal

2012 Invited Jury member (**examiner**): Ph.D. Dissertation of Inês Almeida. ICVS - Universidade do Minho. Braga, Portugal

2012 Invited Jury member (**examiner**): Ph.D. Dissertation of Fatiha Sangar. L'Université Pierre et Marie Curie. Paris, France

2012 Member of the Ph.D. Dissertation Committee of Giovanni Corso. Univ. Porto, Portugal

2012 Invited Jury member (**examiner**): Ph.D. Dissertation of Joana Domingues. Univ. Porto, Portugal



- 2011 Invited Jury member (**examiner**): Ph.D. Dissertation of Bruno Cardoso. Univ. Lisbon, Portugal
- 2011 Member of the Ph.D. Dissertation Committee of Hugo Pinheiro. Univ. Porto, Portugal
- 2011 Member of the Ph.D. Dissertation Committee of Joana Fernandes. Univ. Porto, Portugal
- 2011 Member of the Ph.D. Dissertation Committee of Denisa Mateus. Univ. Aveiro, Portugal
- 2010 Invited Jury member (**examiner**): Masters Dissertation of Rita Domingues. Univ. Porto, Portugal
- 2010 Member of the Ph.D. Dissertation Committee of Sérgia Velho. Univ. Porto, Portugal
- 2010 Member of the Ph.D. Dissertation Committee of Sónia Melo. Univ. Porto, Portugal
- 2009 Invited Jury member (**examiner**): Masters Dissertation of Filipa Sousa. Univ. Porto, Portugal
- 2009 Member of the Ph.D. Dissertation Committee of Joana Simões-Correia. Univ. Porto, Portugal
- 2009 Member of the Ph.D. Dissertation Committee of Ana Rita Mateus. Univ. Porto, Portugal
- 2008 Invited Jury member (**examiner**): Ph.D. Dissertation of Ana Paula Elias. Univ. Lisbon, Portugal
- 2008 Member of the Ph.D. Dissertation Committee of Rachid Karam. Univ. Porto, Portugal
- 2007 Invited Jury member (**examiner**): Masters Dissertation of Renata Carriço. Univ. Lisbon, Portugal
- 2007 Member of the Ph.D. Dissertation Committee of Catarina Castro Alves. Univ. Porto, Portugal

---

## REVIEWING DUTIES

1. **Peer Review Journals:** Journal of Pathology; Oncogene; BMC Cancer; Annals of Human Genetics; European Journal of Human Genetics; Cellular Oncology; Familial Cancer; Future Oncology; Clinical Genetics; European Journal of Cancer; International Journal of Cancer; Carcinogenesis; Virchows Archives; World journal of Gastroenterology; Epigenomics; PlosOne; BMC Genomics; Human Molecular Genetics; Genome Research; Lancet Oncology; Gastroenterology; Frontiers in Genetics; Journal of Medical Genetics
2. **Funding agencies:** Health Research Council of New Zealand; ICS-Institut Clinique de la Souris, France; Dutch Cancer Society (KWF Kankerbestrijding); Portuguese Foundation of Science and Technology (FCT): Research Projects, PhD and Post-doc grant applications (<http://www.fct.pt/apoios/bolsas/concursos/membros?idc=28&idav=38&idp={8AB5E1CF-5699-4213-966A-C2E899921CB0}&show=elems>)

---

## ORAL COMMUNICATIONS – NATIONAL AND INTERNATIONAL – BY INVITATION (n=113)

- 112. “CDH1 LOCUS DISRUPTION: genome-wide functional impacts”. III International Meeting of the Portuguese Society of Genetics, University of Évora. June 2022.
- 111. European Reference Networks (ERNs) workshop, European Human Genetics Conference. June 2022.
- 110. “Prevention and early detection”. Fighting Cancer Session, AICIB. May 2022.
- 109. “Genotype-Phenotype Associations in CDH1 pathogenic and likely pathogenic variant carrier families”. Scientific session: CDH1 & Gastric Cancer Genetics – online. March 2022.
- 108. “TIPS to Get Your Research Project Funded”. LYRIS Course – Online Event. February 2022.
- 107. “The CDH1 and other familial gastric cancer genotype-phenotype associations: an ERN GENTURIS project”. ERN GENTURIS Tumour Predisposition Conference – online. February 2022.
- 106. “Genes supressores tumorais e instabilidade genética”. Lecture on PDMOM/MOM PhD program – Oncobiology course – IPATIMUP, Portugal, January 2022
- 105. “Síndromes ligados ao cancro: o contexto ideal para prevenção” - Breast Center Seminar in CHUSJ. Porto Portugal, December 2021.
- 104. “The Genetics Scientist perspective” - Ethical imperative – the importance of quality on diagnostics and practice in Genetic Medicine. 25th Annual Meeting SPGH – online. November 2021.
- 103. “Gastric cancer: predisposing factors and clinical biomarkers”. III Symposium on Applied Biochemistry in University of Minho. Braga, Portugal, October 2021.

102. "CTNNA1 database". ERN GENTURIS meeting – online. October 2021.
101. "Novos Genes Novas Recomendações" - Thematic Session "New Genes New Recommendations". XI National Congress of Senology. Porto, Portugal, October 2021.
100. "Cancer Epigenetics". 10th Workshop on Cancer Research: Biological and Molecular basis. i3S Porto Portugal, September 2021.
99. "Genotypes vs Phenotypes: Solving the unsolved in Hereditary Diffuse Gastric Cancer". Group Leader Seminar at i3S. Porto, Portugal, April 2021.
98. "Síndromes associados a cancro: o ponto de encontro da investigação em genética humana e da vida real". Questions & Answers (Q & A) 2<sup>nd</sup> Edition. Portuguese Society of Genetics. Porto, Portugal, February 2021.
97. "WP5: Bioinformatics tools to explore cell/EVs contents". TRAIN-EV Virtual Meeting – online. January, 2021.
96. "Familial Gastric Cancer: hidden layers of a genetically heterogeneous Disease". CI-IPOP/EPOP Scientific meeting - Online. May 2020.
95. "Hereditary Diffuse Gastric Cancer: From genes to disease phenotypes". 2019 Seoul International Gastric Cancer Forum. Seoul, South Korea, December 2019.
94. "Molecular determinants of gastric cancer: predisposing factors and intra-tumoral heterogeneity". 3rd Annual Meeting CINBIO. Vigo, Spain, July 2019.
93. "European Reference Networks – What is in it for me?". European Human Genetics Conference (ESHG) 2019. Gothenburg, Sweden, June 2019.
92. "Beyond the coding sequence of CDH1: lessons from Hereditary Diffuse Gastric Cancer syndrome". CEDOC Seminar. Lisbon, Portugal, June 2019.
91. "CDH1 locus inactivation: phenotypes and novel mechanisms". 2019 IGCLC Hereditary Diffuse Gastric Cancer Consensus Clinical Guidelines Meeting. Wanaka, New Zealand, March 2019.
90. "Regulation of the CDH1 locus: Intronic sequences command CDH1 expression". VIII Portuguese Meeting: ptRNA 2019, i3S. Porto, Portugal, January 2019.
89. "Gastric Cancer: novel germline predisposing factors and somatic prognostic markers". Integrative Program Seminar Series: Cancer Research Line, i3S, Porto, Portugal, December 2018
88. "Panel Discussion: What are ERNs and what is in there for me?". Satellite Meeting-European Reference Networks in Portugal on the 22<sup>nd</sup> Annual Meeting SPGH. Porto, Portugal, November 2018
87. "Up-date in Hereditary Gastric Cancer". Session: GENETIC FOR LIFE. The new Frontiers in gastric cancer diagnosis and treatment. Forli, Italy, September 2018
86. "Gastric Cancer: the genetics behind the biology of a lethal disease". Encontro com a Ciência e a Tecnologia em Portugal. Tema - 3 - Saúde de Qualidade – ONCOLOGIA. Lisbon, Portugal, July 2018
85. "Round Table: A PhD for the XXI century". 1<sup>st</sup> i3S PhDay, Porto, Portugal, May 2018
84. "Tumor cell invasion and metastasis: Epithelial to mesenchymal transition and cancer cell plasticity ". Lecture on VII Workshop on Cancer Research, IPATIMUP, Porto, Portugal, May 2018
83. "Presentation of the European Reference Network GENTURIS - Genetic tumour risk syndromes: opportunities to improve health care for patients with hereditary cancer syndromes in Europe". Workshop on 3<sup>rd</sup> ASPIC International Congress, Lisbon, Portugal, May 2018
82. "GEIVEX / Portuguese branch". ISEV2018 Annual Meeting - Meet the National Societies and Outreach Strategies, Barcelona, Spain, May 2018
81. "Hereditary Diffuse Gastric Cancer". Lecture on 2nd Spring Course in Hereditary Cancer Genetics. Bertinoro, Italy, April 2018
80. "Redefining Germline Mechanisms of Disease". Lecture on GABBA Oncobiology Module, Porto, Portugal, March 2018
79. "Horizontally transferable mechanisms in gastric cancer: modulators of cellular behavior and cancer biomarkers". 1<sup>st</sup> Meeting on Vesicular Biology, Coimbra, Portugal, February 2018

78. "Genes supressores tumorais e instabilidade genética". Lecture on PDMOM/MOM PhD program – Oncobiology course – IPATIMUP, Portugal, January 2018
77. "From diseases to causative molecular events: genetic, epigenetic and horizontally transferable mechanisms". Lecture on Molecular Mechanisms of Disease, PhD Program in Health Sciences, FMUC, December 2017
76. "Light and Antibodies Fighting Gastric Cancer". I3S Distinguished Lectures. I3S Annual Meeting 2017, Póvoa de Varzim, Portugal, November 2017
75. "Genetics and gastric cancer". Session: Which diseases are inherited? UEG United European Gastroenterology Week 2017, Barcelona, October 2017
74. "Hereditary gastric cancer". Lecture on post-graduate course - A Multidisciplinary approach to Hereditary GI Cancers: from Bench to Bedside (ESDO-ESGE-InSIGHT), Florence, Italy, July 2017
73. "CDH1 germline noncoding defects: the missing mechanisms in Hereditary Diffuse Gastric Cancer". One Day Symposium with Patrick Tan: Knowns & Unknowns in Gastric Cancer and Other Tumours of the Digestive System, i3S, Porto, Portugal, June 2017
72. "Clinical utility of high-throughput genome analysis and impact for patient treatment". First DOCnet Consortium Meeting, Faculty of Medicine of the University of Porto (FMUP), Portugal, May 2017
71. "microRNAs in screening programs of high risk patients/regions: how far are we?". Esophagus and Gastric Cancer Session. Leaping Forward Oncology – International Clinical Congress 2017, Lisbon, May, 2017
70. "Tumor cell invasion and metastasis: Epithelial to mesenchymal transition and cancer cell plasticity". VII Workshop on Cancer Research, IPATIMUP Porto, Portugal, May 2017
69. "Current challenges in familial gastric cancer". Lecture on Master course - Oncobiologia da Faculdade de Medicina de Lisboa (FMUL) – Módulo de Risco Familiar. Lisbon, Portugal, May, 2017
68. "Oncogenes and Tumor suppressor genes". Invited lecture at ICBAS, Portugal, May, 2017
67. "The translational value of germline and somatic mechanisms for diagnosis and anti-cancer therapy in gastric cancer". Integrative Program Seminar Series: Cancer Research Line, i3S, Porto, Portugal, April 2017
66. "Molecular determinants of gastric cancer: genotypes, phenotypes and impact in progression and treatment". Seminar at Instituto de Saúde Pública da Universidade do Porto (ISPUP), Porto, Portugal March, 2017
65. "Redefining germline mechanisms of disease". Lecture on GABBA Oncobiology Module, Porto, Portugal, February 2017
64. "Genes supressores tumorais e instabilidade genética". Lecture on PDMOM/MOM PhD program – Oncobiology course – IPATIMUP, Portugal, January 2017
63. "From disease to causative gene events: an omics approach in gastric cancer". Keynote Lecture XIX National Congress of Biochemistry, Guimarães, Portugal, December 2016
62. "Current challenges in familial gastric cancer". Symposium update – erbliche gastrointestinale karzinomerkrankungen Munich, Germany November 2016
61. "Molecular determinants of gastric cancer: genotypes, phenotypes and impact in progression and treatment". Seminar series National Cancer Center Research Institute, Tokyo, Japan, August 2016
60. "Cancro gástrico esporádico e familiar: aspectos genéticos". I Congresso da EUROPACOLON Portugal em Oncologia Digestiva. Fundação Cupertino Miranda, Porto, Portugal, July 2016
59. "From single genes to full genomes, from single mechanisms to complex pathways". iBiMED International Advanced Training School. Omics in Biomedicine: linking genes and metabolites, iBiMED Aveiro, Portugal, June 2016
58. "Tumor cell invasion and metastasis: Epithelial to mesenchymal transition and cancer cell plasticity". VI Workshop on Cancer Research, IPATIMUP Porto, Portugal, May 2016
57. "Epigenetic mechanisms of gene expression regulation in gastric cancer". ICVS Course Epigenetics - from mechanisms to disease. Braga, Portugal. April 2016
56. "From single causing genetic mutations to multiple modifying mutations in cancer- the journey of a life-time". III Jornadas da Bioquímica "Bioquímicos pelo Mundo". Porto, Portugal. April 2016

55. "Hereditary Diffuse Gastric Cancer". 1st Spring Course in Hereditary Cancer Genetics. Bertinoro, Italy. April 2016
54. "Effect of cancer cell-derived extracellular vesicles over normal cells from the microenvironment". Spring Meeting of the Cost Action European Network on Microvesicles and Exosomes in Health and Disease, Ioannina, Greece, March 2016
53. "Molecular determinants of cancer: genotypes and phenotypes". iBIMED Seminar Series. Aveiro, Portugal. October 2015
52. "From single causing genetic mutations to multiple modifying mutations in cancer". INEB Summer Science Club: Integrating Competences. Porto, Portugal. July 2015
51. "GASTRIC CANCER THERAPY, THE ERA OF FUNCTIONAL GENOMICS". Post-graduated course "Cancer therapy: from basic research to clinic", Dept. of Biology, University of Minho, Braga, Portugal, June 2015
50. "Genomics and Transcriptomics in cancer research". V Workshop on Cancer Research – Biological and molecular basis. IPATIMUP/ICBAS, Porto, Portugal, May 2015
49. "Genómica e Bioinformática: O que o clínico deve saber". XXXVI Congresso Português de Cardiologia. Albufeira, Portugal, April 2015
48. "The genomics and bioinformatics era: does it help understanding better sporadic and hereditary cancer?" Research Seminar, IPO, Instituto Português de Oncologia, Lisbon, Portugal, February 2015
47. "Using NGS to uncover structural and regulatory variation in gastric cancer" COIMBRA GENOMICS Annual MEETING, CURIA, Portugal, January 2015
46. "Germline and somatic determinants of gastric cancer: Next Generation Sequencing and Functional Genomics". Ministry of Health - MD Anderson Cancer Center Joint Conference on Gastric and Hereditary Cancer, Lisbon Academic Medical Center Lisbon, Portugal, November 2014
45. "Through the looking glass: the reversion of EMT". 1st International Congress ASPIC – Associação Portuguesa de Investigação em Cancro. Lisbon, Portugal, November 2014
44. "Hereditary GI cancer: New genes, old diseases". UEG – United European Gastroenterology Week, Vienna Austria October 2014
43. "The role and cargo of EVs in epithelial-mesenchymal-epithelial transitions and gastric cancer progression". II GEIVEX SYMPOSIUM: Extracellular vesicles, from the bench to the clinics. Satellite Meeting of the Portuguese Groups on Extracellular Vesicles, Taragona, Spain, October 2014
42. "The role and cargo of EVs in epithelial-mesenchymal-epithelial transitions and gastric cancer progression". Autumn Meeting of the Cost action European Network on Microvesicles and Exosomes in Health and Disease, Palermo, Italy, September 2014
41. "Can you use next generation sequencing data from tumours to rationally select targeted therapy approaches?". BioP5med Unworkshop, IGC - Oeiras, Lisbon, Portugal, July 2014
40. "Metastable phenotypes". ONCOBIOLOGY - genes and tumoral microenvironment Seminar Series. Medical Sciences Faculty - NOVA University, Lisbon Portugal May 2014
39. "Germline and somatic determinants in gastric cancer: a focus on E-cadherin". ONCOBIOLOGY - genes and tumoral microenvironment Seminar Series. Medical Sciences Faculty - NOVA University, Lisbon Portugal May 2014
38. "Genomics and Transcriptomics in cancer research". IV Workshop on Cancer Research, IPATIMUP Porto, Portugal, May 2014
37. "Next Generation Sequencing (NGS): Principles and clinical applications". 6th Scientific Meeting of the Portuguese Society of Clinical Chemistry and Laboratorial Medicine, Coimbra, Portugal, April 2014
36. "Germline and somatic determinants in gastric cancer: a focus on E-cadherin". Oncology Meetings: Gastric Cancer - State of Art. University of Minho, Braga, Porto, Portugal, March 2014
35. "Using NGS and in Vitro Models to Understand Structural and Regulatory Variation in Gastric Cancer" Bio-IT World and Cambridge Healthtech Institute's Second Annual, Clinical Genomics and Genome Informatics Europe, Deciphering Disease through Sequencing Data, Lisbon Portugal, December 2013

34. "Using molecular stratification and NGS to Understand Structural and Regulatory Variation in Gastric Cancer" 17th SPGH Annual Meeting, Coimbra Portugal, November 2013
33. "Modulation of cell-cell adhesion in cancer and epithelial-mesenchymal-epithelial transition?" IMM Monday lectures, IMM Lisbon Portugal, November 2013
32. "Metastatic pathways in gastric cancer: is there a role of Extracellular Vesicles?" 2nd Meeting COST Action\_BM1202 ME-HAD, Semmelweis University NET building Budapest Hungary, October 2013
31. "Germline and somatic determinants in gastric cancer - impact in diagnosis, prognosis and treatment". Monday Seminar Medical Faculty University of Porto, Porto Portugal, October 2013
30. "Modulation of E-cadherin expression and function in gastric cancer - clinical and molecular features". 19TH GI CANCER FORUM - The Martin Cohen Lecture Theatre, CRUK CRI - Li Ka Shing Centre, Cambridge UK, September 2013
29. "Molecular mechanisms modulating the function of the invasion suppressor protein E-cadherin". Institut Curie, Université Paris-SUD, Paris, France, July 2013.
28. "HDGC: Updated guidelines for clinical management" IGCC 2013, 10<sup>th</sup> International Gastric Cancer Congress, Verona Italy, June 2013
27. "Cancer Metastization: Examples from the wet lab". III Workshop on Cancer Research, IPATIMUP Porto Portugal May 2013
26. "Genetics of hereditary diffuse gastric cancer – HDGC". Funderburg Symposium - "Current Approach to Hereditary Diffuse Gastric Cancer (HDGC) syndrome". DDW 2013 Digestive Disease Week Orlando, USA, May 2013
25. "From disease to mechanisms: old and new stories about E-cadherin". IMMS - Instituto Mexicano de Seguro Social Guadalajara Mexico, January 2013
24. "Dissecting the role of cadherins with OMICS technologies". Course: "New frontiers of OMICs in Medicine - from the lab to a clinical setting". IBILI Coimbra, Portugal, January 2013
23. "Dissecting the role of cadherins with genome-wide technologies". User Meeting Genómica. IBILI Coimbra, September 2012
22. "Novel molecular mechanisms modulating the function of the invasion suppressor protein E-cadherin". 2<sup>nd</sup> IBEC-INEB Advanced Summer School. IBEC Barcelona, Spain, June 2012
21. "From disease to mechanisms: old and new stories about E-cadherin". CDR Saint-Antoine. Paris, France, April 2012
20. "Epigenetic Changes in Cancer and Epithelial to Mesenchymal Transitions". Mini-symposium on Epigenetics and Cancer. IBMC Porto, Portugal, March 2012
19. "E-cadherin the sticky component of epithelial tissues: old gene new stories". CEDOC. Lisbon, Portugal, May 2011
18. "Tumor cell invasion and metastasis". I Workshop on Cancer Research: biological and molecular basis. Porto, Portugal, May 2011
17. "Regulation of E-cadherin expression and function in cancer". BIOCANT, Coimbra, Portugal, May 2011
16. "Regulatory RNA molecules modulating the function of E-cadherin". Mini-Symposium on "Mechanisms of Gene Expression. IPATIMUP. Porto, Portugal, September 2010
15. "Functions of non-coding RNAs in gene regulation and disease". ICBAS. Porto, April 2010
14. "Coding and non-coding RNAs controlling E-cadherin expression and function". "RNA world: not so small" Life Technologies/Applied Biosystems Symposium. Porto, April 2010
13. "E-cadherin and Hereditary Diffuse Gastric Cancer (HDGC)". I Meeting on Biomedical Sciences. Aveiro, Portugal, March 2010
12. "Functions of non-coding RNAs in gene regulation and disease". Annual Meeting Portuguese Society of Human Genetics. Porto, Portugal, November 2009
11. "Nanoparticles as a vehicle to decrease cancer risk". Symposium 20 years of Biomagical Engineering. Tibães-Braga, Portugal, June 2009

10. "E-cadherin expression regulation in Cancer: new targets of regulation in the E-cadherin locus". Aveiro, Portugal, May 2009
9. "Modulating the expression of E-cadherin (CDH1) in Hereditary Diffuse Gastric Cancer. IGC. Lisbon, Portugal, December 2008
8. "Modulating the expression of E-cadherin (CDH1) in Hereditary Diffuse Gastric Cancer". Annual Meeting Portuguese Society of Human Genetics. Lisbon, Portugal, November 2008
7. "Gastric cancer". Seminars in Biopathology. Faculty of Medicine, Porto, Portugal, January 2008.
6. "Hereditary Diffuse Gastric Cancer (HDGC): The model of E-Cadherin (CDH1)". VuMC, Amsterdam, The Netherlands, October 2007
5. "BRAF and KRAS activating mutations in colorectal carcinogenesis". SINAL – 1st National Meeting on Signal Transduction. Lisbon, Portugal, March 2007
4. "KRAS and BRAF in gastrointestinal neoplasia". INSERM. Paris, France, May 2004
3. "Distinct patterns of KRAS mutations in colorectal carcinomas according to germline Mismatch Repair defects and hMLH1 methylation status". XIII Porto Cancer Meeting: Mismatch repair genes, Microsatellite Instability, and Cancer. Porto, Portugal, May 2004
2. "KRAS and BRAF in MSI gastric and colorectal carcinomas". 10th Multidisciplinary Meeting in Oncology. Lisbon, Portugal, April 2004

---

## ORGANIZATION OF MEETINGS, SEMINARS AND COURSES

- Nov, 2021 Organizer and Chair of the Scientific Program Committee of the Portuguese Society of Human Genetics 2021, Porto, Portugal.
- Aug, 2021 Organizer and Scientific Program Committee Member of the European Human Genetics Virtual Conference ESHG 2021.
- Nov, 2020 Organizer and Chair of the Scientific Program Committee of the Portuguese Society of Human Genetics 2020, Porto, Portugal.
- June, 2020 Organizer and Scientific Program Committee Member of the European Human Genetics Virtual Conference ESHG 2020.2 - Live in Your Living Room.
- Jun, 2020 Organizer of the Workshop "W06 - European Reference Networks –What is in it for me?". European Human Genetics Virtual Conference ESHG 2020.2 - Live in Your Living Room.
- Nov, 2019 Organizer and Chair of the Scientific Program Committee of the Portuguese Society of Human Genetics 2019, Porto, Portugal.
- Nov, 2019 Organizer of the Workshop "Genetic and Oncology: building bridges". 16<sup>th</sup> National Congress of Oncology 2019. Lisbon, Portugal.
- June, 2019 Organizer and Scientific Program Committee Member of the European Human Genetics Conference 2019, Gothenburg, Sweden.
- Jun, 2019 Organizer of the Workshop "European Reference Networks – What is in it for me?". European Human Genetics Conference (ESHG) 2019. Gothenburg, Sweden.
- Nov, 2018 Organizer of the Workshop: "What are ERNs and what is in there for me?". Satellite Meeting-European Reference Networks in Portugal on the 22nd Annual Meeting SPGH. Porto, Portugal.
- Nov, 2018 Organizer and Chair of the Scientific Program Committee of the Portuguese Society of Human Genetics 2018, Porto, Portugal.
- May, 2018 Organizer of the workshop "Presentation of the European Reference Network GENTURIS - Genetic tumour risk syndromes: opportunities to improve health care for patients with hereditary cancer syndromes in Europe". 3<sup>rd</sup> ASPIC International Congress, Lisbon, Portugal.
- June, 2018 Organizer and Scientific Program Committee Member of the European Human Genetics Conference 2018, Milan Italy.
- April, 2018 Co-Organizer of the "2<sup>nd</sup> Spring Course in Hereditary Cancer Genetics". Bertinoro, Italy.

- Nov, 2017 Organizer and Chair of the Scientific Program Committee of the Portuguese Society of Human Genetics 2017, Lisbon, Portugal.
- Nov, 2016 Organizer and Scientific Program Committee Member of the Portuguese Society of Human Genetics 2016, Coimbra, Portugal.
- April, 2016 Co-Organizer of the "1<sup>st</sup> Spring Course in Hereditary Cancer Genetics". Bertinoro, Italy.
- Nov, 2015 Organizer and Scientific Program Committee Member of the Portuguese Society of Human Genetics Annual Meeting 2015. Porto, Portugal.
- Nov, 2014 Organizer and Scientific Program Committee Member of the Portuguese Society of Human Genetics Annual Meeting 2014. Lisboa, Portugal.
- Oct, 2014 Chair of the Session "Gastric cancer: New insights into pathogenesis and management". UEG – United European Gastroenterology Week, Vienna Austria.
- Oct, 2014 Chair of the Session "Mechanisms underlying the development of GI cancer". UEG – United European Gastroenterology Week, Vienna Austria.
- Oct, 2014 Chair of the Session "Clinical perspectives on gastric malignant tumours". UEG – United European Gastroenterology Week, Vienna Austria.
- Nov, 2013 Organizer and Scientific Program Committee Member of the Portuguese Society of Human Genetics Annual Meeting 2013. Coimbra, Portugal.
- June, 2013 Organizer and Scientific Program Committee Member of the European Human Genetics Conference 2013. Paris, France.
- Nov, 2012 Organizer and Scientific Program Committee Member of the Portuguese Society of Human Genetics Annual Meeting 2012. Porto, Portugal.
- June, 2012 Organizer and Scientific Program Committee Member of the European Human Genetics Conference 2012. Nuremberg, Germany.
- June, 2012 Chair of the "Cancer Genetics" session, The European Human Genetics Conference 2012. Nuremberg, Germany.
- May, 2011 Organizer and Scientific Program Committee Member of the European Human Genetics Conference 2011. Amsterdam, The Netherlands.
- Nov, 2011 Organizer and Scientific Program Committee Member of the Portuguese Society of Human Genetics Annual Meeting 2011. Lisbon, Portugal.
- May, 2011 Chair of the "Cancer Genetics" session, The European Human Genetics Conference 2011. Amsterdam, The Netherlands.
- May, 2011 Chair of the "Cancer Genomes" session, The European Human Genetics Conference 2011. Amsterdam, The Netherlands.
- June, 2010 Organizer and Scientific Program Committee Member of the European Human Genetics Conference 2010. Gothenburg, Sweden.
- Nov, 2010 Organizer and Scientific Program Committee Member of the Portuguese Society of Human Genetics Annual Meeting 2010. Coimbra, Portugal.
- Sept, 2010 Organizer of the RNA Symposium- 17th National Congress of Biochemistry. Porto, Portugal.
- June, 2010 Chair of the "Cancer Genetics" session, The European Human Genetics Conference 2010. Gothenburg, Sweden.
- June, 2010 Chair of the "Long Distance Regulation session", The European Human Genetics Conference 2010. Gothenburg, Sweden.
- May, 2010 Chair of the SINAL 2010 – 4th National Meeting on Signal Transduction. Univ. of Algarve; Portugal.
- May, 2009 Chair of the SINAL 2009 – 3rd National Meeting on Signal Transduction. Univ. of Aveiro, Portugal.
- May, 2008 Organizer of the SINAL 2008 – 2nd National Meeting on Signal Transduction. Institute for Molecular and Cell Biology (IBMC), Porto, Portugal.

- May, 2004 Organizer of the XIII Edition Porto Cancer Meeting “Mismatch repair genes, Microsatellite instability, and Cancer”. IPATIMUP; Porto, Portugal.
- May, 2002 Organizer of the XI Edition Porto Cancer Meeting “Familial and hereditary gastric cancer – Meeting of the International Gastric Cancer Linkage Consortium (IGCLC)”. IPATIMUP; Porto, Portugal.

---

## MEMBERSHIPS OF SCIENTIFIC SOCIETIES

- 2017-Present Sociedade Portuguesa de Genética – SPG (Member)
- 2016-2018 European Society for Medical Oncology – ESMO (Member)
- 2014-Present Portuguese Association for Cancer research – ASPIC (Member)
- 2014-Present Grupo Español de Investigación en Vesículas Extracelulares – GEIVEX (Member)
- 2014-Present European Association for Cancer research – EACR (Member)
- 2013-Present European Society of Human Genetics – ESHG (Deputy Secretary General and Scientific Program Committee member)
- 2003-Present Portuguese Society of Human Genetics – SPGH (Chair of the Scientific Program Committee)

---

## PRIZES AND AWARDS (Personal and to the Team)

- 3<sup>rd</sup> Best Poster session from XIII National Meeting of Biochemistry Students 2021 for the project entitled "Characterization of CDH1 and its Antisense Gene in Stomach and Breast Normal Cell Lines" (to Nelson Martins; Carla Oliveira senior author)
- SPGH Professor Amândio Tavares 2021 Award for the oral presentation entitled “The First CDH1 Founder Variant in the Portuguese Population: A Missense with severe Impact in mRNA Splicing” (to Rita Barbosa-Matos; Carla Oliveira senior author)
- Alfredo da Silva Award 2021 on “Sustainability of Health Systems” for the project entitled “Hereditary Breast Ovarian Cancer – HBOC: Optimizing hereditary cancer pathways (saving costs and lives)”. Fundação Amélia de Mello. To Carla Oliveira.
- PRÉMIO CIÊNCIA PULIDO VALENTE 2020 on “Doenças oncológicas-Tumores como ecossistemas de clones e células: implicações terapêuticas” for the work entitled “3D Cellular Architecture Affects MicroRNA and Protein Cargo of Extracellular Vesicles”, published in *Advanced Science*, vol. 6, 4, 180094, 2018 (to Sara Rocha; Carla Oliveira senior author)
- SPGH Professor Amândio Tavares 2020 Award for the oral presentation entitled “THE EMERGING ROLE OF CTNNA1 AS A HEREDITARY DIFFUSE GASTRIC CANCER PREDISPOSING GENE” (to Silvana Lobo; Carla Oliveira senior author)
- 2nd National Meeting of Young Oncology Researchers 2020 “Best Oral Communication” for the oral presentation entitled “*Tumor immune profile reveals a new role for regulatory T cells in the development of gastric cancer*” (to Sara Rocha; Carla Oliveira senior author)
- SPGH Meeting “ESHG National Fellowship 2019” for best presentation on “*The role of CDH1 regulatory noncoding elements for E-cadherin expression*” (to Celina S. José; Carla Oliveira senior author)
- ESHG Meeting “Mia Neri Award for the best talk in cancer research, Award 2019” for the oral presentation entitled “*Structural variations at CDH1 intronic cis-regulatory elements cause CDH1/E-cadherin loss of function*” (to Ana Rita Matos; Carla Oliveira senior author)
- SPGH Meeting “ESHG National Fellowship 2018” for best oral presentation on “*Intronic cis-regulatory elements regulate CDH1 gene expression and function*” (to Ana Rita Matos; Carla Oliveira senior author)
- ESHG Meeting “Best Poster in Clinical Practice award” for the best clinical research work in Oncogenetics and Public Services in a Poster format, 2018 (to Luzia Garrido; Carla Oliveira senior author)
- SPGH Meeting “Prof. Doutor Amândio Tavares, FWA Award” for the best basic research work in Oncogenetics and Public Services in PT, 2017 (to Luzia Garrido; Carla Oliveira senior author)



- V Aaicbas Biomedical Congress / ICBAS "Best Poster Award" in PT, 2017 (to Celina São José; Carla Oliveira senior author)
- Portuguese Society of Oncology for the best basic research work in Oncobiology in PT, 2016 (to Joana Carvalho; Carla Oliveira senior author)
- SPGH Meeting "ESHG National Fellowship 2016" for the best research work in Cancer Genetics in PT 2016 (to Joana Carvalho; Carla Oliveira senior author)
- SPGH Meeting for best basic research work in Human Genetics in PT 2016 (to Sofia Valente; Carla Oliveira senior author)
- No Stomach For Cancer Foundation Award 2014 (to Carla Oliveira and David Huntsman)
- ESHG Meeting "ESHG Poster Award" on basic research work in Human Genetics in Europe, 2011 (to Joana Carvalho; Carla Oliveira senior author)
- 6th Intern. Medical Postgraduate Conference for best PhD work in Europe, 2009 (to Joana Carvalho; Carla Oliveira senior author)
- SPGH Meeting "Young Investigator Award" for best basic research work in Human Genetics in PT 2004 (to Rachid Karam; Carla Oliveira senior author)
- Labmed Prize for Research in health, 2003 (Carla Oliveira co-author)
- SPGH Meeting "Young Investigator Award" for best basic research work in Human Genetics in PT 2002 (to Carla Oliveira)
- Labmed 2nd Prize for Research in health, 2001 (Carla Oliveira co-author)
- Portuguese Rotary Club Portugal Prize for best Research work in Oncobiology in Portugal 1998 (to Carla Oliveira)

---

## APPLIED RESEARCH ACTIVITIES

- 2018 Patent on "BIOMARKER FOR PRENATAL DIAGNOSIS OF TWIN-TO-TWIN TRANSFUSION SYNDROME", (Ref. WO2018011765), in the frame of a collaborative project with Filipa Carvalho and Alexandra Matias from the Faculty of Medicine and Centro Hospitalar S. João in Porto, Portugal.
- 2018 Development of two novel "BIOINFORMATICS ALGORITHMS" by the ERiC research team for NGS quality control and for variant annotation and classification. This knowledge has been applied by the Bioinf2Bio Startup company to provide support to two diagnostic companies.
- 2015-2018 Completion of five bioinformatics projects with the Portuguese Institute of Oncology. These projects aimed at the identification of the missing heritability in cancer families followed by the multidisciplinary team and Oncogenetics consultation of this hospital. Bioinf2Bio Startup company.
- 2015-2018 Completion of 12 bioinformatics research projects with researchers from IBMC, Ipatimup, Icahn School of Medicine at Mount Sinai (USA). Bioinf2Bio Startup company.
- 2015-2018 Completion of 4 bioinformatics projects for the Industry. Bioinf2Bio Startup company.
- 2017 Patent preparation on a novel panel of biomarkers for detection of gastric cancer, after a research project funded by the Company Coimbra Genomics from Portugal and the Beijing Genomics Institute – BGI– from China in 2013 [to be submitted].
- 2005-Present Consultant for cancer-associated syndromes at Ipatimup Diagnostics Unit, with emphasis on syndromes involving gastric cancer, due to expertise in this field of research.

---

## OUTREACH ACTIVITIES

- Participated in more than 50 interviews/documentaries broadcasted on TV, Radio, Internet and Newspapers over the last 15 years.
- One of the 100 Portuguese female scientists featured in the Book "Mulheres na Ciência" CiênciaViva 2016.

- Organized/Participated in several public sessions about science with school kids.
- Organized/Participated in several public sessions about hereditary cancer with patients' associations.

## IN THE MEDIA RECENTLY

Participated in > 40 interviews/documentaries broadcasted on TV, Radio, Internet and Newspapers over the last 15 years.

Recent interviews about the Solve-RD Project and the GENTURIS European Reference Network:

- ✓ “Meu cancro, minha herança?”, Segundas de Conversa da Liga Contra o Cancro: <https://www.facebook.com/ligacontracancro/videos/3062856977302548>
- ✓ “Os cancros que o SNS podia evitar”, Jornal Expresso: <https://expresso.pt/sociedade/2019-03-03-Os-cancros-que-o-SNS-podia-evitar#gs.2sbhao>.
- ✓ “Investigação Científica: Carla Oliveira”, Diário de Notícias: <https://www.dn.pt/edicao-do-dia/26-jan-2019/interior/carla-oliveira-a-verdadeira-prevencao-do-cancro-do-estomago-so-se-faz-pela-historia-familiar--10484310.html>.
- ✓ “Investigadores do i3S recebem 250 mil euros para combater doenças raras”, Notícias U. Porto: <http://noticias.up.pt/investigadores-do-i3s-recebem-250-mil-euros-para-combater-doencas-raras/>.
- ✓ “Ciência: Portugal está na linha da frente da investigação para tratar o cancro”, Notícias Magazine: <https://www.noticiasmagazine.pt/2018/investigacao-contr-o-cancro/>.
- ✓ “Pooling resources for diagnostics of the future”, Notícias i3S: Pooling resources for diagnostics of the future.
- ✓ “i3S Participa em Projeto Internacional de Tratamento das Doenças Raras”, Notícias Porto: <http://www.porto.pt/noticias/i3s-participa-em-projeto-internacional-de-tratamento-das-doencas-raras>.
- ✓ “Bolsa Europeia para Investigação Sobre Doenças Raras”, Notícias IPATIMUP: <https://www.ipatimup.pt/Site/ActivityView.aspx?ActivityId=3076>.
- ✓ “Prevenção Do Cancro Hereditário Traz Benefícios Financeiros Para O Sistema De Saúde”, Notícias UEGWeek'18: <https://uegweek2018.newsfarma.pt>

## CAREER BREAKS

June, 2006 Birth of daughter Sara de Oliveira Maia, 27th June 2006 (Maternity leave)

Sept, 2010 Birth of son José Miguel de Oliveira da Maia, 15th September 2010 (Maternity leave)

## COMPLETE LIST OF PUBLICATION OF CARLA OLIVEIRA

- **H-INDEX = 60** (SCOPUS/ResearcherID) or **62** (GoogleScholar)
- **PUBLICATIONS: 172 peer-reviewed articles** in the fields of Human Genetics and Molecular Oncology
- **Accumulated Impact Factor >1.000,00**
- **Number of citations:** 11.607 times (9.449 excluding self-citations SCOPUS/ResearcherID) or > 17.528 times (GoogleScholar)

Oliveira C position in each paper reference has been highlighted in bold and underlined (**Oliveira C**)

Paper correspondence has been highlighted with (#);

Co-authorship has been highlighted with an asterisk (\*).

**2022**

175. Baião A, Dias S, Soares AF, Pereira CL, **Oliveira C**, Sarmiento B. Advances in the use of 3D colorectal cancer models for novel drug discovery. **Expert Opin Drug Discov.** 2022 ;17(6):569-580. doi: 10.1080/17460441.2022.2056162. Epub 2022 Mar 27. PMID: 35343351.
174. Coudert M, Drouet Y, Delhomelle H, Svrcek M, Benusiglio PR, Coulet F, Clark DF, Katona BW, van Hest LP, van der Kolk LE, Cats A, van Dieren JM, Nehoray B, Slavin T, Spier I, Hüneburg R, Lobo S, **Oliveira C**, Boussemart L, Masson L, Chiesa J, Schwartz M, Buecher B, Golmard L, Bouvier AM, Bonadona V, Stoppa-Lyonnet D, Lasset C, Colas C. First estimates of diffuse gastric cancer risks for carriers of *CTNNA1* germline pathogenic variants. **J Med Genet.** 2022 Aug 29;jmedgenet-2022-108740. doi: 10.1136/jmg-2022-108740. Epub ahead of print. PMID: 36038258.
173. Santos M, Fidalgo A, Varanda AS, Soares AR, Almeida GM, Martins D, Mendes N, **Oliveira C<sup>#</sup>**, Santos MAS<sup>#</sup>. Upregulation of tRNA-Ser-AGA-2-1 Promotes Malignant Behavior in Normal Bronchial Cells. **Front Mol Biosci.** 2022 May 2; 9:809985. doi: 10.3389/fmolb.2022.809985. PMID: 35586191; PMCID: PMC9108184.
172. Santos M, Ferreira M, Oliveira P, Mendes N, André A, Vieira AF, Nunes JB, Carvalho J, Rocha S, Azevedo M, Ferreira D, Reis I, Vinagre J, Paredes J, Heravi-Moussavi A, Lima J, Máximo V, Burleigh A, Roskelley C, Carneiro F, Huntsman D, **Oliveira C<sup>#</sup>**. 2022. Epithelial-Mesenchymal Plasticity Induced by Discontinuous Exposure to TGFβ1 Promotes Tumour Growth. **Biology** 11, 1046. doi:10.3390/biology11071046
171. Sommer AK, Te Paske IBAW, Garcia-Pelaez J, Laner A, Holinski-Feder E, Steinke-Lange V, Peters S, Valle L, Spier I, Huntsman D; Solve-RD-GENTURIS group. Solving the genetic aetiology of hereditary gastrointestinal tumour syndromes- a collaborative multicentre endeavour within the project Solve-RD. **Eur J Med Genet.** 2022 Mar 10:104475. doi: 10.1016/j.ejmg.2022.104475. Epub ahead of print. PMID: 35283344.
170. Pereira C, Park JH, Campelos S, Gullo I, Lemos C, Solorzano L, Martins D, Gonçalves G, Leitão D, Lee HJ, Kong SH, André A, Borges C, Almeida D, Wälbhy C, Almeida R, Kim WH, Carneiro F, Yang HK, Almeida GM, **Oliveira C<sup>#</sup>**. Comparison of East-Asia and West-Europe cohorts explains disparities in survival outcomes and highlights predictive biomarkers of early gastric cancer aggressiveness. **Int J Cancer.** 2022 Mar 1;150(5):868-880. doi: 10.1002/ijc.33872. Epub 2021 Dec 9. PMID: 34751446.
169. Garcia-Pelaez, J., Barbosa-Matos, R., São José, C., Sousa, S., Gullo, I., Hoogerbrugge, N., Carneiro, F., **Oliveira, C.<sup>#</sup>**, 2022. Gastric cancer genetic predisposition and clinical presentations: Established heritable causes and potential candidate genes. **European Journal of Medical Genetics** 65, 104401. doi:10.1016/j.ejmg.2021.104401

## 2021

168. Lobo S, Benusiglio PR, Coulet F, Boussemart L, Golmard L, Spier I, Hüneburg R, Aretz S, Colas C, **Oliveira C<sup>#</sup>**. Cancer predisposition and germline CTNNA1 variants. **Eur J Med Genet.** 2021 Oct;64(10):104316. doi: 10.1016/j.ejmg.2021.104316. Epub 2021 Aug 21. PMID: 34425242.
167. Matalonga L, Hernández-Ferrer C, Piscia D; Solve-RD SNV-indel working group, Schüle R, Synofzik M, Töpf A, Vissers LELM, de Voer R; Solve-RD DITF-GENTURIS; Solve-RD DITF-ITHACA; Solve-RD DITF-euroNMD; Solve-RD DITF-RND, Tonda R, Laurie S, Fernandez-Callejo M, Picó D, Garcia-Linares C, Papakonstantinou A, Corvó A, Joshi R, Diez H, Gut I, Hoischen A, Graessner H, Beltran S; **Solve-RD Consortium**. Solving patients with rare diseases through programmatic reanalysis of genome-phenome data. **Eur J Hum Genet.** 2021 Sep;29(9):1337-1347. doi: 10.1038/s41431-021-00852-7. Epub 2021 Jun 1. Erratum in: Eur J Hum Genet. 2021 Aug 16;; PMID: 34075210; PMCID: PMC8440686.
166. Zurek B, Ellwanger K, Vissers LELM, Schüle R, Synofzik M, Töpf A, de Voer RM, Laurie S, Matalonga L, Gilissen C, Ossowski S, 't Hoen PAC, Vitobello A, Schulze-Hentrich JM, Riess O, Brunner HG, Brookes AJ, Rath A, Bonne G, Gumus G, Verloes A, Hoogerbrugge N, Evangelista T, Harmuth T, Swertz M, Spalding D, Hoischen A, Beltran S, Graessner H; **Solve-RD consortium**. Correction to: Solve-RD: systematic pan-European data sharing and collaborative analysis to solve rare diseases. **Eur J Hum Genet.** 2021 Sep;29(9):1459-1461. doi: 10.1038/s41431-021-00936-4. Erratum for: **Eur J Hum Genet.** 2021 Sep;29(9):1325-1331. PMID: 34385672; PMCID: PMC8440583.

165. Schüle R, Timmann D, Erasmus CE, Reichbauer J, Wayand M; Solve-RD-DITF-RND, van de Warrenburg B, Schöls L, Wilke C, Bevot A, Zuchner S, Beltran S, Laurie S, Matalonga L, Graessner H, Synofzik M; **Solve-RD Consortium**. Correction: Solving unsolved rare neurological diseases—a Solve-RD viewpoint. *Eur J Hum Genet*. 2021 Sep;29(9):1462-1465. doi: 10.1038/s41431-021-00935-5. Erratum for: *Eur J Hum Genet*. 2021 Sep;29(9):1332-1336. PMID: 34429526; PMCID: PMC8440676.
164. Barbosa-Matos R, Leal Silva R, Garrido L, Aguiar AC, Garcia-Pelaez J, André A, Seixas S, Sousa SP, Ferro L, Vilarinho L, Gullo I, Devezas V, Oliveira R, Fernandes S, Costa SC, Magalhães A, Baptista M, Carneiro F, Pinheiro H, Castedo S, **Oliveira C<sup>#</sup>**. The CDH1 c.1901C>T Variant: A Founder Variant in the Portuguese Population with Severe Impact in mRNA Splicing. *Cancers* (Basel). 2021 Sep 4;13(17):4464. doi: 10.3390/cancers13174464. PMID: 34503274; PMCID: PMC8430675.
163. Almeida GM, Pereira C, Park JH, Lemos C, Campelos S, Gullo I, Martins D, Gonçalves G, Leitão D, Neto JL, André A, Borges C, Almeida D, Lee HJ, Kong SH, Kim WH, Carneiro F, Almeida R, Yang HK, **Oliveira C<sup>#</sup>**. CD44v6 High Membranous Expression Is a Predictive Marker of Therapy Response in Gastric Cancer Patients. *Biomedicines*. 2021 Sep 18;9(9):1249. doi: 10.3390/biomedicines9091249. PMID: 34572441; PMCID: PMC8465138.
162. Te Paske IBAW, Garcia-Pelaez J, Sommer AK, Matalonga L, Starzynska T, Jakubowska A; Solve-RD-GENTURIS group, van der Post RS, Lubinski J, **Oliveira C**, Hoogerbrugge N, de Voer RM. A mosaic PIK3CA variant in a young adult with diffuse gastric cancer: case report. *Eur J Hum Genet*. 2021 Jun 1. doi: 10.1038/s41431-021-00853-6. Epub ahead of print. PMID: 34075207.
161. Tedaldi G, Molinari C, São José C, Barbosa-Matos R, André A, Danesi R, Arcangeli V, Ravegnani M, Saragoni L, Morgagni P, Rebuzzi F, Canale M, Pignatta S, Ferracci E, Martinelli G, Ranzani GN, **Oliveira C<sup>#</sup>**, Calistri D, Ulivi P. Genetic and Epigenetic Alterations of CDH1 Regulatory Regions in Hereditary and Sporadic Gastric Cancer. *Pharmaceuticals* (Basel). 2021 May 12;14(5):457. doi: 10.3390/ph14050457. PMID: 34066170; PMCID: PMC8151134.
160. Ferreira DA, Rothbauer M, Conde JP, Ertl P, **Oliveira C**, Granja PL. A Fast Alternative to Soft Lithography for the Fabrication of Organ-on-a-Chip Elastomeric-Based Devices and Microactuators. *Adv Sci* (Weinh). 2021 Feb 8;8(8):2003273. doi: 10.1002/advs.202003273. PMID: 33898174; PMCID: PMC8061392.
159. Garcia-Pelaez J, Barbosa-Matos R, Gullo I, Carneiro F, **Oliveira C<sup>#</sup>**. Histological and mutational profile of diffuse gastric cancer: current knowledge and future challenges. *Mol Oncol*. 2021 Mar 16. doi: 10.1002/1878-0261.12948. Epub ahead of print. PMID: 33724653.
158. Lourenço BN, Pereira RF, Barrias CC, Fischbach C, **Oliveira C**, Granja PL. Engineering Modular Half-Antibody Conjugated Nanoparticles for Targeting CD44v6-Expressing Cancer Cells. *Nanomaterials* (Basel). 2021 Jan 23;11(2):295. doi: 10.3390/nano11020295. PMID: 33498669; PMCID: PMC7912417.
157. Rocha S, Basto AP, Ijsselsteijn ME, Teles SP, Azevedo MM, Gonçalves G, Gullo I, Almeida GM, Maqueda JJ, Oliveira MI, Carneiro F, Barata JT, Graça L, de Miranda NFCC, Carvalho J, **Oliveira C<sup>#</sup>**. Immunophenotype of Gastric Tumors Unveils a Pleiotropic Role of Regulatory T Cells in Tumor Development. *Cancers* (Basel). 2021 Jan 23;13(3):421. doi: 10.3390/cancers13030421. PMID: 33498681; PMCID: PMC7865950.
156. Osório H, Silva C, Ferreira M, Gullo I, Máximo V, Barros R, Mendonça F, **Oliveira C**, Carneiro F. Proteomics Analysis of Gastric Cancer Patients with Diabetes Mellitus. *Journal of Clinical Medicine*. 2021; 10(3):407. <https://doi.org/10.3390/jcm10030407>.

## **2020**

155. Evans DG, Woodward ER, Bajalica-Lagercrantz S, **Oliveira C**, Frebourg T. Germline TP53 Testing in Breast Cancers: Why, When and How? *Cancers* (Basel). 2020 Dec 14;12(12):3762. doi: 10.3390/cancers12123762. PMID: 33327514; PMCID: PMC7764913.

154. Blair VR, McLeod M, Carneiro F, Coit DG, D'Addario JL, van Dieren JM, Harris KL, Hoogerbrugge N, **Oliveira C**, van der Post RS, Arnold J, Benusiglio PR, Bisseling TM, Boussioutas A, Cats A, Charlton A, Schreiber KEC, Davis JL, Pietro MD, Fitzgerald RC, Ford JM, Gamet K, Gullo I, Hardwick RH, Huntsman DG, Kaurah P, Kupfer SS, Latchford A, Mansfield PF, Nakajima T, Parry S, Rossaak J, Sugimura H, Svrcek M, Tischkowitz M, Ushijima T, Yamada H, Yang HK, Claydon A, Figueiredo J, Paringatai K, Seruca R, Bougen-Zhukov N, Brew T, Busija S, Carneiro P, DeGregorio L, Fisher H, Gardner E, Godwin TD, Holm KN, Humar B, Lintott CJ, Monroe EC, Muller MD, Norero E, Nouri Y, Paredes J, Sanches JM, Schulpen E, Ribeiro AS, Sporle A, Whitworth J, Zhang L, Reeve AE, Guilford P. Hereditary diffuse gastric cancer: updated clinical practice guidelines. **Lancet Oncol**. 2020 Aug;21(8):e386-e397. doi: 10.1016/S1470-2045(20)30219-9. PMID: 32758476.
153. Lobo S, Pereira C, **Oliveira C<sup>#,\*</sup>**, Almeida GM. Skipping Exon-v6 from CD44v6-Containing Isoforms Influences Chemotherapy Response and Self-Renewal Capacity of Gastric Cancer Cells. **Cancers** (Basel). 2020 Aug 22;12(9):E2378. doi: 10.3390/cancers12092378. PMID: 32842638.
152. Sousa A, Ferreira M, **Oliveira C<sup>#,\*</sup>**, Ferreira PG. Gender Differential Transcriptome in Gastric and Thyroid Cancers. **Front Genet**. 2020 Jul 30;11:808. doi: 10.3389/fgene.2020.00808. PMID: 32849808; PMCID: PMC7406663.
151. Tischkowitz M, Colas C, Pouwels S, Hoogerbrugge N; PHTS Guideline Development Group; European Reference Network GENTURIS. Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome [published online ahead of print, 2020 Jun 12]. **Eur J Hum Genet**. 2020;10.1038/s41431-020-0651-7. doi:10.1038/s41431-020-0651-7.
150. Frebourg T, Bajalica Lagercrantz S, **Oliveira C**, Magenheimer R, Evans DG; European Reference Network GENTURIS. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes [published online ahead of print, 2020 May 26]. **Eur J Hum Genet**. 2020;10.1038/s41431-020-0638-4. doi:10.1038/s41431-020-0638-4.
149. Gullo I, Costa C, Silva SL, Ferreira C, Motta A, Silva SP, Ferreira RD, Rosmaninho P, Faria E, Costa JTD, Câmara R, Gonçalves G, Santos-Antunes J, **Oliveira C**, Machado JC, Carneiro F, Sousa AE. The Dysfunctional Immune System in Common Variable Immunodeficiency Increases the Susceptibility to Gastric Cancer. **Cells**. 2020 Jun 19;9(6):1498. doi: 10.3390/cells9061498. PMID: 32575504; PMCID: PMC7349552.
148. Baião A, Sousa F, Oliveira AV, **Oliveira C**, Sarmiento B. Effective intracellular delivery of bevacizumab via PEGylated polymeric nanoparticles targeting the CD44v6 receptor in colon cancer cells. **Biomater Sci**. 2020 Jul 7;8(13):3720-3729. doi: 10.1039/d0bm00556h. Epub 2020 Jun 5. PMID: 32500879.
147. Leclercq P, Jadot V, Bours V, **Oliveira C**, Neumann H, Bisschops R. Inherited CDH1 pathogenic variant: is there a place for surveillance of esophageal gastric inlet patch? **Therap Adv Gastroenterol**. 2020 Apr 28;13:1756284820916399. doi: 10.1177/1756284820916399. PMID: 32523621; PMCID: PMC7236565.
146. Pereira C, Ferreira D, Mendes N, Granja PL, Almeida GM, **Oliveira C<sup>#</sup>**. Expression of CD44v6-Containing Isoforms Influences Cisplatin Response in Gastric Cancer Cells. **Cancers** (Basel). 2020 Apr 2;12(4):858. doi: 10.3390/cancers12040858. PMID: 32252293; PMCID: PMC7226224.
145. Devezas V, Baptista M, Gullo I, Rocha J, Sousa F, Xiaogang W, Preto J, Costa S, Castedo S, Garrido L, **Oliveira C**, Barbosa E, Carneiro F, Barbosa J. Risk-reducing total gastrectomy in asymptomatic CDH1 carriers. **Eur Surg**. 2020. <https://doi.org/10.1007/s10353-020-00630-7>.
144. Carvalho J, Oliveira P, Senz J, SJ Celina, Hansford S, Teles SP, Ferreira M, Corso G, Pinheiro H, Lemos D, Pascale V, Roviello F, Huntsman D, **Oliveira C<sup>#</sup>**. Redefinition of familial intestinal gastric cancer: clinical and genetic perspectives. **Journal of Medical Genetics** Published Online First: 17 February 2020. doi: 10.1136/jmedgenet-2019-106346.

## 2019

143. Vos JR, Giepmans L, Röhl C, Geverink N, Hoogerbrugge N; **ERN GENTURIS**. Boosting care and knowledge about hereditary cancer: European Reference Network on Genetic Tumour Risk Syndromes. **Fam Cancer**. 2019;18(2):281-284. doi:10.1007/s10689-018-0110-6.
142. Teles SP, Oliveira P, Ferreira M, Carvalho J, Ferreira P, **Oliveira C<sup>#</sup>**. Integrated Analysis of Structural Variation and RNA Expression of FGFR2 and Its Splicing Modulator ESRP1 Highlight the ESRP1(amp)-FGFR2(norm)-FGFR2-IIIc(high) Axis in Diffuse Gastric Cancer. **Cancers** (Basel). 2019 Dec 25;12(1). pii: E70. doi: 10.3390/cancers12010070. PubMed PMID: 31881796.
141. Varanda AS, Santos M, Soares AR, Vitorino R, Oliveira P, **Oliveira C**, Santos MAS. Human cells adapt to translational errors by modulating protein synthesis rate and protein turnover. **RNA Biol**. 2020 Jan;17(1):135-149. doi: 10.1080/15476286.2019.1670039. Epub 2019 Oct 1. PubMed PMID: 31570039; PubMed Central PMCID: PMC6948982.
140. Carneiro P, Moreira AM, Figueiredo J, Barros R, Oliveira P, Fernandes MS, Ferro A, Almeida R, **Oliveira C**, Carneiro F, Schmitt F, Paredes J, Velho S, Seruca R. S100P is a molecular determinant of E-cadherin function in gastric cancer. **Cell Commun Signal**. 2019 Nov 25;17(1):155. doi: 10.1186/s12964-019-0465-9. PubMed PMID: 31767037; PubMed Central PMCID: PMC6878717.
130. Tedaldi G, Pirini F, Tebaldi M, Zampiga V, Cangini I, Danesi, R, Arcangeli V, Ravegnani M, Abou Khouzam R, Molinari C, **Oliveira C**, Morgagni P, Saragoni L, Bencivenga M, Ulivi P, Amadori D, Martinelli G, Falcini F, Ranzan GN, Calistri D. Multigene Panel Testing Increases the Number of Loci Associated with Gastric Cancer Predisposition. **Cancers** 11, 1340. 2019 September. Doi: 10.3390/cancers11091340.
138. Slavin TP, Weitzel JN, Neuhausen SL, Schrader KA, **Oliveira C**, Karam R. Genetics of gastric cancer: what do we know about the genetic risks? **Translational Gastroenterology and Hepatology**. 2019 July. 4:55. Doi: 10.21037/tgh.2019.07.02.
137. van der Post RS, **Oliveira C\***, Guilford P, Carneiro F. Hereditary gastric cancer: what's new? Update 2013–2018. **Familial Cancer**. 2019 July. 18: 363. Doi: 10.1007/s10689-019-00127-7.
136. Dueñas M, Pérez-Figueroa A, **Oliveira C\***, Suárez-Cabrera C, Sousa A, Oliveira P, Villacampa F, Paramio JM, Martínez-Fernández M. Gene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status. **Scientific Reports Nature in press**. 2019 June 25. Doi: 10.1038/s41598-019-46652-4. PubMed PMID: 31316092.
135. Santos M, Fidalgo A, Varanda AS, **Oliveira C<sup>#,\*</sup>**, Santos MAS. tRNA Deregulation and Its Consequences in Cancer. **Trends in Molecular Medicine**. 2019 June 24. ISSN 1471-4914. Doi:10.1016/j.molmed.2019.05.011.
134. Rocha S, Teles SP, Azevedo M, Oliveira P, Carvalho J, **Oliveira C<sup>#</sup>**. Gastric Cancer Extracellular Vesicles Tune the Migration and Invasion of Epithelial and Mesenchymal Cells in a Histotype-Dependent Manner. **International Journal of Molecular Sciences**. 2019 May 28;20(11). Doi: 10.3390/ijms20112608. PubMed PMID: 31141946.
133. Härkönen K, Oikari S, Kyykallio H, Capra J, Hakkola S, Ketola K, Thanigai Arasu U, Daaboul G, Malloy A, **Oliveira C**, Jokelainen O, Sironen R, Hartikainen JM, Rilla K. CD44s Assembles Hyaluronan Coat on Filopodia and Extracellular Vesicles and Induces Tumorigenicity of MKN74 Gastric Carcinoma Cells. **Cells**. 2019; 8(3):276. Doi: 10.3390/cells8030276.
132. Bustos-Carpinteyro AR, **Oliveira C**, Sousa A, Oliveira P, Pinheiro H, Carvalho J, Magaña-Torres MT, Flores-Miramontes MG, Aguilar-Lemarroy A, Jave-Suárez LF, Peregrina-Sandoval J, Cruz-Ramos JA, Sánchez-López JY. CDH1 somatic alterations in Mexican patients with diffuse and mixed sporadic gastric cancer. **BMC Cancer**. 2019 Jan 14;19(1):69. Doi: 10.1186/s12885-019-5294-0. PubMed PMID: 30642281.

## 2018

131. Lourenço BN, Dos Santos T, **Oliveira C**, Barrias CC, Granja PL. Bioengineering a novel 3D in vitro model of gastric mucosa for stomach permeability studies. **Acta biomaterialia**. 2018; 82:68-78. Doi: 10.1016/j.actbio.2018.10.007 PubMed [journal] PMID: 30308252.
130. Rocha S, Carvalho J, Oliveira P, Voglstaetter M, Schwartz D, Thomsen AR, Walter N, Khanduri R, Sanchez JC, Keller A, **Oliveira C<sup>#,\*</sup>**, Nazarenko I\*. 3D Cellular Architecture Affects MicroRNA and Protein Cargo of Extracellular Vesicles. **Advanced Science**. Dec, 2018. Doi: 10.1002/advs.201800948.
129. Pereira C, Ferreira D, Lemos C, Martins D, Mendes N, Almeida D, Granja P, Carneiro F, Almeida R, Almeida GM, **Oliveira C<sup>#</sup>**. CD44v6 expression is a novel predictive marker of therapy response and poor prognosis in gastric cancer patients. **BioRxiv** 468934. Nov, 2018. Doi: 10.1101/468934.
128. Lee K, Krempely K, Roberts ME, Anderson MJ, Carneiro F, Chao E, Dixon K, Figueiredo J, Ghosh R, Huntsman D, Kaurah P, Kesserwan C, Landrith T, Li S, Mensenkamp AR, **Oliveira C**, Pardo C, Pesaran T, Richardson M, Slavin TP, Spurdle AB, Trapp M, Witkowski L, Yi CS, Zhang L, Plon SE, Schrader KA, Karam R. Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline CDH1 sequence variants. **Human Mutation**. 2018 Nov;39(11):1553-1568. Doi: 10.1002/humu.23650. PubMed PMID: 30311375; PubMed Central PMCID: PMC6188664.
127. Solorzano L, Almeida GM, Mesquita B, Martins D, **Oliveira C**, Wählby C. (2018) Whole Slide Image Registration for the Study of Tumor Heterogeneity. In: Stoyanov D. et al. (eds) Computational Pathology and Ophthalmic Medical Image Analysis. OMIA 2018, COMPAY 2018. **Lecture Notes in Computer Science**, vol 11039. Springer, Cham. Doi: 10.1007/978-3-030-00949-6\_12.
126. Kennedy PJ, Sousa F, Ferreira D, Pereira C, Nestor M, **Oliveira C**, Granja PL, Sarmento B. Fab-conjugated PLGA nanoparticles effectively target cancer cells expressing human CD44v6. **Acta Biomater**. 2018 Sep 26. pii: S1742-7061(18)30572-5. Doi: 10.1016/j.actbio.2018.09.043. [Epub ahead of print] PubMed PMID: 30267881.
125. Gullo I, Carvalho J, Martins D, Lemos D, Monteiro AR, Ferreira M, Das K, Tan P, **Oliveira C**, Carneiro F, Oliveira P. The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors. **International Journal of Molecular Sciences**. 2018 Jul 17;19(7) pii: E2079. Doi: 10.3390/ijms19072079. PubMed PMID: 30018250.
124. Rocha JP, Gullo I, Wen X, Devezas V, Baptista M, **Oliveira C**, Carneiro F. Pathological features of total gastrectomy specimens from asymptomatic hereditary diffuse gastric cancer patients and implications for clinical management. **Histopathology** 73, 878–886. 2018 December. Doi: 10.1111/his.13715. Review. PubMed PMID: 30014492.
123. Lima JF, Carvalho J, Pinto-Ribeiro I, Almeida C, Wengel J, Cerqueira L, Figueiredo C, **Oliveira C**, Azevedo NF. Targeting miR-9 in gastric cancer cells using locked nucleic acid oligonucleotides. **BMC Molecular Biology**. 2018 Jun 7;19(1):6. Doi:10.1186/s12867-018-0107-6. PubMed PMID: 29879907; PubMed Central PMCID: PMC5992815.
122. Santos M, Pereira PM, Varanda AS, Carvalho J, Azevedo M, Mateus DD, Mendes N, Oliveira P, Trindade F, Pinto MT, Bordeira-Carriço R, Carneiro F, Vitorino R, **Oliveira C<sup>\*,#</sup>**, Santos MAS<sup>\*,#</sup>. Codon misreading tRNAs promote tumor growth in mice. **RNA Biology**. 2018 Jun 7:1-14. Doi: 10.1080/15476286.2018.1454244. [Epub ahead of print] PubMed PMID: 29558247.
121. Gullo I, Devezas V, Baptista M, Garrido L, Castedo S, Morais R, Wen X, Rios E, Pinheiro J, Pinto-Ribeiro I, Ferreira RM, Preto J, Santos-Antunes J, Marques M, Campos M, Almeida F, Espinheira MDC, Amil Dias J, Figueiredo C, **Oliveira C**, Trindade E, Carneiro F. Phenotypic heterogeneity of hereditary diffuse gastric cancer: report of a family with early-onset disease. **Gastrointestinal Endoscopy**. 2018 Jun;87(6):1566-1575. Doi: 10.1016/j.gie.2018.02.008. Epub 2018 Feb 15. PubMed PMID: 29454568.
120. Gullo I, Oliveira P, Atheologou M, Gonçalves G, Pinto ML, Carvalho J, Valente A, Pinheiro H, Andrade S, Almeida GM, Huss R, Das K, Tan P, Machado JC, **Oliveira C**, Carneiro F. New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression. **Gastric Cancer**. 2018 May 19. Doi: 10.1007/s10120-018-0836-8. [Epub ahead of print] PubMed PMID:29779068.

119. Kennedy PJ, **Oliveira C**, Granja PL, Sarmiento B. Monoclonal antibodies: technologies for early discovery and engineering. **Critical Reviews in Biotechnology**. 2018 May; 38(3):394-408. Doi: 10.1080/07388551.2017.1357002. Epub 2017 Aug 8. PubMed PMID: 28789584.
118. Kennedy PJ, Ferreira I, Ferreira D, Nestor M, **Oliveira C**, Granja PL, Sarmiento B. Impact of surfactants on the target recognition of Fab-conjugated PLGA nanoparticles. **Eur J Pharm Biopharm**. 2018 Jun; 127:366-370. Doi: 10.1016/j.ejpb.2018.03.005. Epub 2018 Mar 13. PubMed PMID: 29549023.
117. Lima JF, Cerqueira L, Figueiredo C, **Oliveira C**, Azevedo NF. Anti-miRNA oligonucleotides: A comprehensive guide for design. **RNA Biology**. 2018 Mar 4;15(3):338-532. Doi: 10.1080/15476286.2018.1445959. Epub 2018 Mar 23. PubMed PMID: 29570036; PubMed Central PMCID: PMC5927725.
116. Lourenço BN, Springer NL, Ferreira D, **Oliveira C**, Granja PL, Fischbach C. CD44v6 increases gastric cancer malignant phenotype by modulating adipose stromal cell-mediated ECM remodeling. **Integr Biol (Camb)**. 2018 Mar 1;10(3):145-158. Doi: 10.1039/c7ib00179g. Epub 2018 Feb 16. PubMed PMID: 29450424; PubMed Central PMCID: PMC5988203.
115. Ferreira PG, Muñoz-Aguirre M, Reverter F, Sá Godinho CP, Sousa A, Amadoz A, Sodaei R, Hidalgo MR, Pervouchine D, Carbonell-Caballero J, Nurtdinov R, Breschi A, Amador R, Oliveira P, Çubuk C, Curado J, Aguet F, **Oliveira C**, Dopazo J, Sammeth M, Ardlie KG, Guigó R. The effects of death and post-mortem cold ischemia on human tissue transcriptomes. **Nature Communications**. 2018 Feb 13;9(1):490. Doi: 10.1038/s41467-017-02772-x. PubMed PMID: 29440659; PubMed Central PMCID: PMC5811508.
114. Weren RDA, van der Post RS, Vogelaar IP, van Krieken JH, Spruijt L, Lubinski J, Jakubowska A, Teodorczyk U, Aalfs CM, van Hest LP, **Oliveira C**, Kamping EJ, Schackert HK, Ranzani GN, Gómez García EB, Hes FJ, Holinski-Feder E, Genuardi M, Ausems MGEM, Sijmons RH, Wagner A, van der Kolk LE, Cats A, Bjørnevoll I, Hoogerbrugge N, Ligtenberg MJL. Role of germline aberrations affecting CTNNA1, MAP3K6 and MYD88 in gastric cancer susceptibility. **J Med Genet**. 2018 Jan 12. pii: jmedgenet-2017-104962. Doi: 10.1136/jmedgenet-2017-104962. [Epub ahead of print] PubMed PMID: 29330337.

## **2017**

113. Korsak B, Almeida GM, Rocha S, Pereira C, Mendes N, Osório H, Pereira PMR, Rodrigues JMM, Schneider RJ, Sarmiento B, Tomé JPC\*, **Oliveira C**<sup>#</sup>. Porphyrin modified trastuzumab improves efficacy of HER2 targeted photodynamic therapy of gastric cancer. **Int J Cancer**. 2017 Oct 1;141(7):1478-1489. Doi: 10.1002/ijc.30844. Epub 2017 Jul 10. PubMed PMID: 28639285
112. Kennedy PJ, **Oliveira C**, Granja PL, Sarmiento B. Antibodies and associates: Partners in targeted drug delivery. **Pharmacol Ther**. 2017 Sep; 177:129-145. Doi: 10.1016/j.pharmthera.2017.03.004. Epub 2017 Mar 14. Review. PubMed PMID: 28315359.
111. Vogelaar IP, van der Post RS, van Krieken JHJ, Spruijt L, van Zelst-Stams WA, Kets CM, Lubinski J, Jakubowska A, Teodorczyk U, Aalfs CM, van Hest LP, Pinheiro H, **Oliveira C**, Jhangiani SN, Muzny DM, Gibbs RA, Lupski JR, de Ligt J, Vissers LELM, Hoischen A, Gilissen C, van de Vorst M, Goeman JJ, Schackert HK, Ranzani GN, Molinaro V, Gómez García EB, Hes FJ, Holinski-Feder E, Genuardi M, Ausems MGEM, Sijmons RH, Wagner A, van der Kolk LE, Bjørnevoll I, Høberg-Vetti H, van Kessel AG, Kuiper RP, Ligtenberg MJL, Hoogerbrugge N. Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing. **Eur J Hum Genet**. 2017 Sep 6. Doi: 10.1038/ejhg.2017.138. PubMed PMID: 28875981; PubMed Central PMCID: PMC5643972.
110. Laundos TL, Silva J, Assunção M, Quelhas P, Monteiro C, **Oliveira C**, Oliveira MJ, Pêgo AP, Amaral IF. Rotary orbital suspension culture of embryonic stem cell-derived neural stem/progenitor cells: impact of hydrodynamic culture on aggregate yield, morphology and cell phenotype. **J Tissue Eng Regen Med**. 2017 Aug;11(8):2227-2240. Doi:10.1002/term.2121. Epub 2016 Feb 15. PubMed PMID:26880706.
109. Gullo I, Carneiro F, **Oliveira C**, Almeida GM. Heterogeneity in Gastric Cancer: From Pure Morphology to Molecular Classifications. **Pathobiology**. 2018;85(1-2):50-63. Doi: 10.1159/000473881. Epub 2017 Jun 16. PubMed PMID: 28618420.

## **2016**

108. Oliveira P, Carvalho J, Rocha S, Azevedo M, Reis I, Camilo V, Sousa B, Valente S, Paredes J, Almeida R, Huntsman D, **Oliveira C**<sup>#</sup>. *Dies1*/VISTA expression loss is a recurrent event in gastric cancer due to epigenetic regulation. **Sci Rep**. 2016 Oct 10; 6:34860. Doi: 10.1038/srep34860. PubMed PMID: 27721458; PubMed Central PMCID: PMC5056517.



107. Martins-Marques T, Pinho MJ, Zuzarte M, **Oliveira C**, Pereira P, Sluijter JP, Gomes C, Girao H. Presence of Cx43 in extracellular vesicles reduces the cardiotoxicity of the anti-tumour therapeutic approach with doxorubicin. **J Extracell Vesicles**. 2016 Sep 29; 5:32538. Doi: 10.3402/jev. v5.32538. eCollection 2016. PubMed PMID: 27702427; PubMed Central PMCID: PMC5045474.
106. van der Post RS\*, Gullo I\*, **Oliveira C**, Tang LH, Grabsch HI, O'Donovan M, Fitzgerald RC, van Krieken H, Carneiro F. Histopathological, Molecular, and Genetic Profile of Hereditary Diffuse Gastric Cancer: Current Knowledge and Challenges for the Future. **Adv Exp Med Biol**. 2016; 908:371-91. Doi:10.1007/978-3-319-41388-4\_18. PubMed PMID: 27573781.
105. Bidarra SJ, Oliveira P, Rocha S, Saraiva DP, **Oliveira C**\*, Barrias CC\*. A 3D in vitro model to explore the inter-conversion between epithelial and mesenchymal states during EMT and its reversion. **Sci Rep**. 2016 Jun 3; 6:27072. Doi:10.1038/srep27072. PubMed PMID: 27255191.
104. Fais S, O'Driscoll L, Borrás FE, Buzas E, Camussi G, Cappello F, Carvalho J, Cordeiro da Silva A, Del Portillo H, El Andaloussi S, Ficko Trček T, Furlan R, Hendrix A, Gursel I, Kralj-Iglic V, Kaeffer B, Kosanovic M, Lekka ME, Lipps G, Logozzi M, Marcilla A, Sammar M, Llorente A, Nazarenko I, **Oliveira C**, Pocsfalvi G, Rajendran L, Raposo G, Rohde E, Siljander P, van Niel G, Vasconcelos MH, Yáñez-Mó M, Yliperttula ML, Zarovni N, Zavec AB, Giebel B. Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine. **ACS Nano**. 2016 Apr 26;10(4):3886-99. Doi:10.1021/acsnano.5b08015. Epub 2016 Mar 15. PubMed PMID: 26978483.
103. Vogelaar IP, Ligtenberg MJ, van der Post RS, de Voer RM, Kets CM, Jansen TJ, Jacobs L, Schreiber G; **International Gastric Cancer Genetics Group**, de Vries IJ, Netea MG, Hoogerbrugge N. Recurrent candidiasis and early-onset gastric cancer in a patient with a genetically defined partial MYD88 defect. **Fam Cancer**. 2016 Apr;15(2):289-96. Doi: 10.1007/s10689-015-9859-z. PubMed PMID: 26700889; PubMed Central PMCID: PMC4803817.

## **2015**

102. Queirós P, Pinheiro H, Carvalho J, Oliveira P, Gullo I, Carneiro F, Almeida GM, **Oliveira C**#. KRAS mutations in microsatellite instable gastric tumours: impact of targeted treatment and intratumoural heterogeneity. **Virchows Arch**. 2015 Oct;467(4):383-92. Doi: 10.1007/s00428-015-1823-7. Epub 2015 Aug 29. PubMed PMID: 26318594.
101. Alves S, Castro L, Fernandes MS, Francisco R, Castro P, Priault M, Chaves SR, Moyer MP, **Oliveira C**, Seruca R, Côte-Real M, Sousa MJ, Preto A. Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy. **Oncotarget**. 2015 Oct 13;6(31):30787-802. Doi: 10.18632/oncotarget.5021. PubMed PMID: 26418750; PubMed Central PMCID: PMC4741568.
100. Magalhães A, Marcos-Pinto R, Nairn AV, Dela Rosa M, Ferreira RM, Junqueira-Neto S, Freitas D, Gomes J, Oliveira P, Santos MR, Marcos NT, Xiaogang W, Figueiredo C, **Oliveira C**, Dinis-Ribeiro M, Carneiro F, Moremen KW, David L, Reis CA. Helicobacter pylori chronic infection and mucosal inflammation switches the human gastric glycosylation pathways. **Biochim Biophys Acta**. 2015 Sep;1852(9):1928-39. Doi: 10.1016/j.bbadis.2015.07.001. Epub 2015 Jul 2. PubMed PMID: 26144047. PubMed Central PMCID: PMC4638172.
90. van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, Caldas C, Schreiber KE, Hardwick RH, Ausems MG, Bardram L, Benusiglio PR, Bisseling TM, Blair V, Bleiker E, Boussioutas A, Cats A, Coit D, DeGregorio L, Figueiredo J, Ford JM, Heijkoop E, Hermens R, Humar B, Kaurah P, Keller G, Lai J, Ligtenberg MJ, O'Donovan M, **Oliveira C**, Pinheiro H, Ragunath K, Rasenberg E, Richardson S, Roviello F, Schackert H, Seruca R, Taylor A, Ter Huurne A, Tischkowitz M, Joe ST, van Dijk B, van Grieken NC, van Hillegersberg R, van Sandick JW, Vehof R, van Krieken JH, Fitzgerald RC. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. **J Med Genet**. 2015 Jun;52(6):361-74. Doi: 10.1136/jmedgenet-2015-103094. Epub 2015 May 15. Review. PubMed PMID: 25979631; PubMed Central PMCID: PMC4453626.
98. Caires HR, Gomez-Lazaro M, Oliveira CM, Gomes D, Mateus DD, **Oliveira C**, Barrias CC, Barbosa MA, Almeida CR. Finding and tracing human MSC in 3D microenvironments with the photoconvertible protein Dendra2. **Sci Rep**. 2015 May 14; 5:10079. Doi: 10.1038/srep10079. PubMed PMID: 25974085; PubMed Central PMCID: PMC4431349.
97. Yáñez-Mó M, Siljander PR, Andreu Z, Zavec AB, Borrás FE, Buzas EI, Buzas K, Casal E, Cappello F, Carvalho J, Colás E, Cordeiro-da Silva A, Fais S, Falcon-Perez JM, Ghobrial IM, Giebel B, Gimona M, Graner M, Gursel I, Gursel M, Heegaard NH, Hendrix A, Kierulf P, Kokubun K, Kosanovic M, Kralj-Iglic V, Krämer-Albers EM, Laitinen S, Lässer C, Lener T, Ligeti E, Linē A, Lipps G, Llorente A, Lötval J, Manček-Keber M, Marcilla A,

Mittelbrunn M, Nazarenko I, Nolte-'t Hoen EN, Nyman TA, O'Driscoll L, Olivan M, **Oliveira C**, Pállinger É, Del Portillo HA, Reventós J, Rigau M, Rohde E, Sammar M, Sánchez-Madrid F, Santarém N, Schallmoser K, Ostenfeld MS, Stoorvogel W, Stukelj R, Van der Grein SG, Vasconcelos MH, Wauben MH, De Wever O. Biological properties of extracellular vesicles and their physiological functions. **J Extracell Vesicles**. 2015 May 14; 4:27066. Doi: 10.3402/jev.v4.27066. eCollection 2015. PubMed PMID: 25979354; PubMed Central PMCID: PMC4433489.

96. Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, Schrader KA, Schaeffer DF, Shumansky K, Zogopoulos G, Santos TA, Claro I, Carvalho J, Nielsen C, Padilla S, Lum A, Talhouk A, Baker-Lange K, Richardson S, Lewis I, Lindor NM, Pennell E, MacMillan A, Fernandez B, Keller G, Lynch H, Shah SP, Guilford P, Gallinger S, Corso G, Roviello F, Caldas C, **Oliveira C**, Pharoah PD, Huntsman DG. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. **JAMA Oncol**. 2015 Apr;1(1):23-32. Doi: 10.1001/jamaoncol.2014.168. PubMed PMID: 26182300.
95. Pinheiro H, Oliveira P, **Oliveira C**. Hereditary cancer risk assessment: challenges for the next-gen sequencing era. **Front Oncol**. 2015 Mar 23; 5:62. Doi: 10.3389/fonc.2015.00062. eCollection 2015. Review. PubMed PMID: 25853090; PubMed Central PMCID: PMC4370032.
94. **Oliveira C**, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. Familial Gastric Cancer: genetic susceptibility, pathology and implications for management. **Lancet Oncol**. 2015 Feb;16(2):e60-e70. Doi: 10.1016/S1470-2045(14)71016-2. Review. PubMed PMID: 25638682.
93. Carvalho J, **Oliveira C**. Extracellular Vesicles - Powerful Markers of Cancer Evolution. **Front Immunol**. 2015 Jan 12; 5:685. Doi: 10.3389/fimmu.2014.00685. eCollection 2014. PubMed PMID: 25628624; PubMed Central PMCID: PMC4290688.

#### **2014**

92. Pinheiro H\*, **Oliveira C\***, Seruca R, Carneiro F. Hereditary diffuse gastric cancer - pathophysiology and clinical management. **Best Pract Res Clin Gastroenterol**. 2014 Dec;28(6):1055-68. Epub 2014 Sep 28. PubMed PMID: 25439071.
91. Ferreira AM, Tuominen I, Sousa S, Gerbens F, van Dijk-Bos K, Osinga J, Kooi KA, Sanjabi B, Esendam C, **Oliveira C**, Terpstra P, Hardonk M, van der Sluis T, Zazula M, Stachura J, van der Zee AG, Hollema H, Sijmons RH, Aaltonen LA, Seruca R, Hofstra RM, Westers H. New target genes in endometrial tumors show a role for the estrogen-receptor pathway in microsatellite-unstable cancers. **Hum Mutat**. 2014 Dec;35(12):1514-23. Doi: 10.1002/humu.22700. PubMed PMID: 25231886.
90. Gaston D\*, Hansford S\*, **Oliveira C**, Nightingale M, Pinheiro H, Macgillivray C, Kaurah P, Rideout AL, Steele P, Soares G, Huang WY, Whitehouse S, Blowers S, LeBlanc MA, Jiang H, Greer W, Samuels ME, Orr A, Fernandez CV, Majewski J, Ludman M, Dyack S, Penney LS, McMaster CR, Huntsman D, Bedard K. Germline mutations in MAP3K6 are associated with familial gastric cancer. **PLoS Genet**. 2014 Oct 23;10(10):e1004669. Doi: 10.1371/journal.pgen.1004669. eCollection 2014 Oct. PubMed PMID: 25340522; PubMed Central PMCID: PMC4207611.
89. Bordeira-Carriço R, Ferreira D, Mateus DD, Pinheiro H, Pêgo AP, Santos MA, **Oliveira C#**. Rescue of wild-type E-cadherin expression from nonsense-mutated cancer cells by a suppressor-tRNA. **Eur J Hum Genet**. 2014 Sep;22(9):1085-92. Doi:10.1038/ejhg.2013.292. Epub 2014 Jan 15. PubMed PMID: 24424122; PubMed Central PMCID: PMC4135406.
88. Carneiro F, Wen X, Seruca R, **Oliveira C#**. Familial gastric carcinoma. **Diagnostic Histopathology**. 2014 April; 20(6):239-246. Doi: 10.1016/j.mpdhp.2014.03.010.
87. Durães C, Almeida GM, Seruca R, **Oliveira C#**, Carneiro F. Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? **Virchows Arch**. 2014 Mar;464(3):367-78. Doi: 10.1007/s00428-013-1533-y. Epub 2014 Feb 1. PubMed PMID: 24487788.

#### **2013**

86. Pinho SS, Carvalho S, Marcos-Pinto R, Magalhães A, **Oliveira C**, Gu J, Dinis-Ribeiro M, Carneiro F, Seruca R, Reis CA. Gastric cancer: adding glycosylation to the equation. **Trends Mol Med**. 2013 2013 Nov;19(11):664-76. Doi: 10.1016/j.molmed.2013.07.003. Epub 2013 Aug 8. Review. PubMed PMID: 23932995.
85. **Oliveira C#**, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. E-cadherin alterations in hereditary disorders with emphasis on hereditary diffuse gastric cancer. **Prog Mol Biol Transl Sci**. 2013; 116:337-59. Doi:10.1016/B978-0-12-394311-8.00015-7. PubMed PMID: 23481202.

84. de-Freitas-Junior JC, Carvalho S, Dias AM, Oliveira P, Cabral J, Seruca R, **Oliveira C**, Morgado-Díaz JA, Reis CA, Pinho SS. Insulin/IGF-I signaling pathways enhances tumor cell invasion through bisecting GlcNAc N-glycans modulation. An interplay with E-cadherin. **PLoS One**. 2013 Nov 25;8(11):e81579. Doi: 10.1371/journal.pone.0081579. eCollection 2013. PubMed PMID: 24282611; PubMed Central PMCID: PMC3839884.
83. Carneiro P, Figueiredo J, Bordeira-Carriço R, Fernandes MS, Carvalho J, **Oliveira C<sup>#</sup>**, Seruca R. Therapeutic targets associated to E-cadherin dysfunction in gastric cancer. **Expert Opin Ther Targets**. 2013 Oct;17(10):1187-201. Doi: 10.1517/14728222.2013.827174. Epub 2013 Aug 19. Review. PubMed PMID: 23957294.
82. **Oliveira C<sup>\*</sup>**, Seruca R, Hoogerbrugge N, Ligtenberg M, Carneiro F. Clinical utility gene card for: Hereditary diffuse gastric cancer (HDGC). **Eur J Hum Genet**. 2013 Aug;21(8). Doi: 10.1038/ejhg.2012.247. Epub 2013 Feb 27. PubMed PMID: 23443028; PubMed Central PMCID: PMC3722670.
81. Pereira B, Sousa S, Barros R, Carreto L, Oliveira P, **Oliveira C**, Chartier NT, Plateroti M, Rouault JP, Freund JN, Billaud M, Almeida R. CDX2 regulation by the RNA-binding protein MEX3A: impact on intestinal differentiation and stemness. **Nucleic Acids Res**. 2013 Apr;41(7):3986-99. Doi: 10.1093/nar/gkt087. Epub 2013 Feb 13. PubMed PMID: 23408853; PubMed Central PMCID: PMC3627580.
80. Corso G\*, Carvalho J\*, Marrelli D, Vindigni C, Carvalho B, Seruca R, Roviello F, **Oliveira C<sup>#</sup>**. Somatic mutations and deletions of the E-cadherin gene predict poor survival of gastric cancer patients. **J Clin Oncol**. 2013 Mar 1;31(7):868-75. Doi: 10.1200/JCO.2012.44.4612. Epub 2013 Jan 22. PubMed PMID: 23341533.
79. Fernandes MS, Carneiro F, **Oliveira C**, Seruca R. Colorectal cancer and RASSF family - a special emphasis on RASSF1A. **Int J Cancer**. 2013 Jan 15;132(2):251-8. Doi: 10.1002/ijc.27696. Epub 2012 Jul 14. Review. PubMed PMID: 22733432.

## 2012

78. Paredes J, Figueiredo J, Albergaria A, Oliveira P, Carvalho J, Ribeiro AS, Caldeira J, Costa AM, Simões-Correia J, Oliveira MJ, Pinheiro H, Pinho SS, Mateus R, Reis CA, Leite M, Fernandes MS, Schmitt F, Carneiro F, Figueiredo C, **Oliveira C**, Seruca R. Epithelial E- and P-cadherins: Role and clinical significance in cancer. **Biochim Biophys Acta**. 2012 Dec;1826(2):297-311. Doi: 10.1016/j.bbcan.2012.05.002. Epub 2012 May 19. Review. PubMed PMID: 22613680.
77. Bordeira-Carriço R, Pêgo AP, Santos M, **Oliveira C<sup>#</sup>**. Cancer syndromes and therapy by stop-codon readthrough. **Trends Mol Med**. 2012 Nov;18(11):667-78. Doi: 10.1016/j.molmed.2012.09.004. Epub 2012 Oct 6. Review. PubMed PMID: 23044248.
76. Pinheiro H, Carvalho J, Oliveira P, Ferreira D, Pinto MT, Osório H, Licastro D, Bordeira-Carriço R, Jordan P, Lazarevic D, Sanges R, Stupka E, Huntsman D, Seruca R, **Oliveira C<sup>#</sup>**. Transcription initiation arising from E-cadherin/CDH1 intron2: a novel protein isoform that increases gastric cancer cell invasion and angiogenesis. **Hum Mol Genet**. 2012 Oct 1;21(19):4253-69. Doi: 10.1093/hmg/ddc248. Epub 2012 Jun 29. PubMed PMID: 22752307.
75. Carvalho J, Grieken NCv, Pereira PM, Sousa S, Tijssen M, Buffart TE, Diosdado D, Grabsch H, Santos MA, Meijer G, Seruca R, Carvalho B, **Oliveira C<sup>#</sup>**. Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. **J Pathol**. 2012 Sep;228(1):31-44. Doi: 10.1002/path.4032. Epub 2012 May 23. PubMed PMID: 22450781.
74. Carneiro P, Fernandes MS, Figueiredo J, Caldeira J, Carvalho J, Pinheiro H, Leite M, Melo S, Oliveira P, Simões-Correia J, Oliveira MJ, Carneiro F, Figueiredo C, Paredes J, **Oliveira C**, Seruca R. E-cadherin dysfunction in gastric cancer - Cellular consequences, clinical applications and open questions. **FEBS Lett**. 2012 Aug 31;586(18):2981-9. Doi: 10.1016/j.febslet.2012.07.045. Epub 2012 Jul 25. Review. PubMed PMID: 22841718.
73. Caldeira J, Simões-Correia J, Paredes J, Pinto MT, Sousa S, Corso G, Marrelli D, Roviello F, Pereira PS, Weil D, **Oliveira C**, Casares F, Seruca R. (2011): CPEB1, a novel gene silenced in Gastric Cancer - a Drosophila approach. **Gut**. 2012 Aug;61(8):1115-23. Doi: 10.1136/gutjnl-2011-300427. Epub 2011 Nov 3. PubMed PMID:22052064.
72. Oliveira P, Sanges R, Huntsman DG, Stupka E, **Oliveira C<sup>#</sup>**. Characterization of the intronic portion of cadherin superfamily members, common cancer orchestrators. **Eur J Hum Genet**. 2012 F Aug;20(8):878-

83. Doi: 10.1038/ejhg.2012.11. Epub 2012 Feb 8. PubMed PMID: 22317972; PubMed Central PMCID: PMC3400724
71. Kluijlt I, Siemerink EJ, Ausems MG, van Os TA, de Jong D, Simões-Correia J, van Krieken JH, Ligtenberg MJ, Figueiredo J, van Riel E, Sijmons RH, Plukker JT, van Hillegersberg R, Dekker E, **Oliveira C**, Cats A, Hoogerbrugge N; on behalf of the Dutch Working Group on Hereditary Gastric Cancer. CDH1-related hereditary diffuse gastric cancer syndrome: Clinical variations and implications for counseling. **Int J Cancer**. 2012 Jul 15;131(2):367-76. Doi: 10.1002/ijc.26398. Epub 2011 Oct 23. PubMed PMID: 22020549.
70. Pinho SS\*, Oliveira P\*, Cabral J, Carvalho S, Seruca R, Reis C\*, **Oliveira C**\*#. Loss and recovery of Mgat3 and GnT-III Mediated E-cadherin N-glycosylation is a mechanism involved in epithelial-mesenchymal-epithelial transitions. **PLoS One**. 2012;7(3):e33191. Doi: 10.1371/journal.pone.0033191. Epub 2012 Mar 13. PubMed PMID: 22427986; PubMed Central PMCID: PMC3302839.
69. Simões-Correia J, Figueiredo J, Lopes R, Stricher F, **Oliveira C**, Serrano L, Seruca R. (2012) E-Cadherin Destabilization Accounts for the Pathogenicity of Missense Mutations in Hereditary Diffuse Gastric Cancer. **PLoS ONE**. 2012; 7(3): e33783 Doi: 10.1371/journal.pone.0033783. Epub 2012 Mar 21. PubMed PMID: 22470475; PubMed Central PMCID: PMC3309996.
68. Lopes N, Carvalho J, Durães C, Sousa B, Gomes M, Costa JL, **Oliveira C**, Paredes J, Schmitt F. 1Alpha, 25-dihydroxyvitamin D3 induces de novo E-cadherin expression in triple-negative breast cancer cells by CDH1-promoter demethylation. **Anticancer Res**. 2012 Jan;32(1):249-57. PubMed PMID: 22213313.

## 2011

67. Leite M, Corso G, Sousa S, Milanezi F, Afonso LP, Henrique R, Soares JM, Castedo S, Carneiro F, Roviello F, **Oliveira C**, Seruca R. MSI phenotype and MMR alterations in familial and sporadic gastric cancer. **Int J Cancer**. 2011 Apr 1;128(7):1606-13. Doi: 10.1002/ijc.25495. Epub 2010 Jun 7. PubMed PMID: 20533283.
66. Corso G, Pedrazzani C, Pinheiro H, Fernandes E, Marrelli D, Rinnovati A, Pascale V, Seruca R, **Oliveira C**#, Roviello F. E-cadherin genetic screening and clinico-pathologic characteristics of early onset gastric cancer. **Eur J Cancer**. 2011 Mar;47(4):631-9. Doi: 10.1016/j.ejca.2010.10.011. Epub 2010 Nov 22. PubMed PMID: 21106365.
65. Corso G, Velho S, Paredes J, Pedrazzani C, Martins D, Milanezi F, Pascale V, Vindigni C, Pinheiro H, Leite M, Marrelli D, Sousa S, Carneiro F, **Oliveira C**, Roviello F, Seruca R. Oncogenic mutations in gastric cancer with microsatellite instability. **Eur J Cancer**. 2011 Feb;47(3):443-51. Doi: 10.1016/j.ejca.2010.09.008. PubMed PMID: 20937558.

## 2010

64. da Cunha CB, **Oliveira C**, Wen X, Gomes B, Sousa S, Suriano G, Grellier M, Huntsman DG, Carneiro F, Granja PL, Seruca R. De novo expression of CD44 variants in sporadic and hereditary gastric cancer. **Lab Invest**. 2010 Nov;90(11):1604-1614. Doi: 10.1038/labinvest.2010.155. Epub 2010 Sep 20. PubMed PMID: 20856229.
63. Svrcek M, Buhard O, Colas C, Coulet F, Dumont S, Massaoudi I, Lamri A, Hamelin R, Cosnes J, **Oliveira C**, Seruca R, Gaub MP, Legrain M, Collura A, Lascols O, Tiret E, Fléjou JF, Duval A. Methylation tolerance due to an O6-methylguanine DNA methyltransferase (MGMT) field defect in the colonic mucosa: an initiating step in the development of mismatch repair-deficient colorectal cancers. **Gut**. 2010 Nov;59(11):1516-1526. Doi: 10.1136/gut.2009.194787. PubMed PMID: 20947886.
62. Albergaria A, Ribeiro AS, Pinho S, Milanezi F, Carneiro V, Sousa B, Sousa S, **Oliveira C**, Machado JC, Seruca R, Paredes J, Schmitt F. ICI 182, 780 induces P-cadherin overexpression in breast cancer cells through chromatin remodelling at the promoter level: a role for C/EBPbeta in CDH3 gene activation. **Hum Mol Genet**. 2010 Jul 1;19(13):2554-66. Doi: 10.1093/hmg/ddq134. Epub 2010 Apr 12. PubMed PMID: 20385540.
61. Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, Chung DC, Norton J, Ragnauth K, Van Krieken JH, Dwerryhouse S, Caldas C; International Gastric Cancer Linkage Consortium. *Collaborators: ...*, **Oliveira C**, ... Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. **J Med Genet**. 2010 Jul;47(7):436-44. Doi: 10.1136/jmg.2009.074237. Erratum in: *J Med Genet*. 2011 Mar;48(3):216. Van Krieken, Nicola [corrected to Van Grieken, Nicola C]. PubMed PMID: 20591882; PubMed Central PMCID: PMC2991043.
60. Carneiro F, **Oliveira C**, Seruca R. Pathology and genetics of familial gastric cancer. **Int J Surg Pathol**. 2010 Jun;18(3 Suppl):33S-36S. Doi:10.1177/1066896910366463. PubMed PMID:20484258.

59. Velho S, Corso G, **Oliveira C**, Seruca R. KRAS signaling pathway alterations in microsatellite unstable gastrointestinal cancers. **Adv Cancer Res.** 2010; 109:123-43. Doi: 10.1016/B978-0-12-380890-5.00004-1. PubMed PMID:21070916.
58. Pinheiro H, Bordeira-Carriço R, Seixas S, Carvalho J, Senz J, Oliveira P, Inácio P, Gusmão L, Rocha J, Huntsman D, Seruca R, **Oliveira C**<sup>#</sup>. Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. *Hum Mol Genet.* 2010 Mar 1;19(5):943-952. Doi: 10.1093/hmg/ddp537. Epub 2009 Dec 4. PubMed PMID:19965908; PubMed Central PMCID: PMC2816607.
57. Velho S, **Oliveira C**, Paredes J, Sousa S, Leite M, Matos P, Milanezi F, Ribeiro AS, Mendes N, Licastro D, Karhu A, Oliveira MJ, Ligtenberg M, Hamelin R, Carneiro F, Lindblom A, Peltomaki P, Castedo S, Schwartz S, Jordan P, Aaltonen LA, Hofstra RMW, Suriano G, Stupka E, Fialho AM, Seruca R; Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours. **Human Molecular Genetics**, Volume 19, Issue 4. 15 February 2010, Pages 697–706. Doi: 10.1093/hmg/ddp536

## **2009**

56. Borie C, Colas C, Dartigues P, Lazure T, Rince P, Buhard O, Folliot P, Chalastanis A, Muleris M, Hamelin R, Mercier D, **Oliveira C**, Seruca R, Chadburn A, Leblond V, Barete S, Gaïdano G, Martin A, Gaulard P, Fléjou JF, Raphael M, Duval A. The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms. **Int J Cancer.** 2009 Nov 15;125(10):2360-2366. Doi: 10.1002/ijc.24681. PubMed PMID: 19551857.
55. Pereira B, **Oliveira C**, David L, Almeida R. CDX2 promoter methylation is not associated with mRNA expression. **Int J Cancer.** 2009 Oct 1;125(7):1739-1742. Doi:10.1002/ijc.24544. PubMed PMID: 19569237.
54. Gonçalves CM, Castro MA, Henriques T, Oliveira MI, Pinheiro HC, **Oliveira C**, Sreenu VB, Evans EJ, Davis SJ, Moreira A, Carmo AM. Molecular cloning and analysis of SSc5D, a new member of the scavenger receptor cysteine-rich superfamily. **Mol Immunol.** 2009 Aug;46(13):2585-96. Doi: 10.1016/j.molimm.2009.05.006. Epub 2009 Jun 16. PubMed PMID: 19535143.
53. **Oliveira C**<sup>#</sup>, Sousa S, Pinheiro H, Karam R, Bordeira-Carriço R, Senz J, Kaurah P, Carvalho J, Pereira R, Gusmão L, Wen X, Cipriano MA, Yokota J, Carneiro F, Huntsman D, Seruca R. Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. **Gastroenterology.** 2009 Jun;136(7):2137-2148. Doi: 10.1053/j.gastro.2009.02.065. Epub 2009 Mar 6. PubMed PMID: 19269290.
52. **Oliveira C**, Senz J, Kaurah P, Pinheiro H, Sanges R, Haegert A, Corso G, Schouten J, Fitzgerald R, Vogelsang H, Keller G, Dwerryhouse S, Grimmer D, Chin SF, Yang HK, Jackson CE, Seruca R, Roviello F, Stupka E, Caldas C, Huntsman D. Germline CDH1 deletions in hereditary diffuse gastric cancer families. **Hum Mol Genet.** 2009 May 1;18(9):1545-1555. Doi: 10.1093/hmg/ddp046. Epub 2009 Jan 24. PubMed PMID: 19168852; PubMed Central PMCID: PMC2667284.
51. **Oliveira C**, Seruca R, Carneiro F. Hereditary gastric cancer. **Best Pract Res Clin Gastroenterol.** 2009;23(2):147-57. Doi: 10.1016/j.bpg.2009.02.003. PubMed PMID: 19414142.
50. Seruca R, Velho S, **Oliveira C**, Leite M, Matos P, Jordan P. Unmasking the role of KRAS and BRAF pathways in MSI colorectal tumors. **Expert Rev Gastroenterol Hepatol.** 2009 Feb;3(1):5-9. Doi: 10.1586/17474124.3.1.5. PubMed PMID: 19210107.
49. Velho S, **Oliveira C**, Seruca R. KRAS mutations and anti-epidermal growth factor receptor therapy in colorectal cancer with lymph node metastases. **J Clin Oncol.** 2009 Jan 1;27(1):158-9; author reply 159. Doi: 10.1200/JCO.2008.20.1525. PubMed PMID: 19047277.
48. Pinto C, Veiga I, Pinheiro M, Peixoto A, Pinto A, Lopes JM, Reis RM, **Oliveira C**, Baptista M, Roque L, Regateiro F, Cirnes L, Hofstra RM, Seruca R, Castedo S, Teixeira MR. TP53 germline mutations in Portugal and genetic modifiers of age at cancer onset. **Fam Cancer.** 2009;8(4):383-390. Doi: 10.1007/s10689-009-9251-y. PubMed PMID: 19468865.

## **2008.**

47. Simões-Correia J, Figueiredo J, **Oliveira C**, van Hengel J, Seruca R, van Roy F, Suriano G. Endoplasmic reticulum quality control: a new mechanism of E-cadherin regulation and its implication in cancer. **Hum Mol Genet.** 2008 Nov 15;17(22):3566-76. Doi: 10.1093/hmg/ddn249. Epub 2008 Sep 4. PubMed PMID: 18772194.

46. Carneiro F, **Oliveira C**, Leite M, Seruca R. Molecular targets and biological modifiers in gastric cancer. *Semin Diagn Pathol*. 2008 Nov;25(4):274-87. PubMed PMID: 19013893.
45. Woo MM, Salamanca CM, Miller M, Symowicz J, Leung PC, **Oliveira C**, Ehlen TG, Gilks CB, Huntsman D, Auersperg N. Serous borderline ovarian tumors in long-term culture: phenotypic and genotypic distinction from invasive ovarian carcinomas. *Int J Gynecol Cancer*. 2008 Nov-Dec;18(6):1234-47. Doi:10.1111/j.1525-1438.2007.01171.x. PubMed PMID: 18217967.
44. Barber M, Murrell A, Ito Y, Maia AT, Hyland S, **Oliveira C**, Save V, Carneiro F, Paterson AL, Grehan N, Dwerryhouse S, Lao-Sirieix P, Caldas C, Fitzgerald RC. Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. *J Pathol*. 2008 Nov;216(3):295-306. Doi: 10.1002/path.2426. PubMed PMID:18788075.
43. Velho S, Moutinho C, Cirnes L, Albuquerque C, Hamelin R, Schmitt F, Carneiro F, **Oliveira C**, Seruca R. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? *BMC Cancer*. 2008 Sep 9; 8:255. Doi: 10.1186/1471-2407-8-255. PubMed PMID: 18782444; PubMed Central PMCID: PMC2553419.
42. Matos P, **Oliveira C**, Velho S, Gonçalves V, da Costa LT, Moyer MP, Seruca R, Jordan P. B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival. *Gastroenterology*. 2008 Sep;135(3):899-906. Doi: 10.1053/j.gastro.2008.05.052. Epub 2008 May 22. PubMed PMID: 18602919.
41. Karam R, Carvalho J, Bruno I, Graziadio C, Senz J, Huntsman D, Carneiro F, Seruca R, Wilkinson MF, **Oliveira C**. The NMD mRNA surveillance pathway downregulates aberrant E-cadherin transcripts in gastric cancer cells and in CDH1 mutation carriers. *Oncogene*. 2008 Jul 10;27(30):4255-60. Doi:10.1038/onc.2008.62. Epub 2008 Apr 21. PubMed PMID: 18427545.
40. Preto A, Figueiredo J, Velho S, Ribeiro AS, Soares P, **Oliveira C**, Seruca R. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations. *J Pathol*. 2008 Feb;214(3):320-7. PubMed PMID: 18098337.
39. Carneiro F, **Oliveira C**, Suriano G, Seruca R. Molecular pathology of familial gastric cancer, with an emphasis on hereditary diffuse gastric cancer. *J Clin Pathol*. 2008 Jan;61(1):25-30. PubMed PMID: 17513507.

## **2007**

38. Masciari S, Larsson N, Senz J, Boyd N, Kaurah P, Kandel MJ, Harris LN, Pinheiro HC, Troussard A, Miron P, Tung N, **Oliveira C**, Collins L, Schnitt S, Garber JE, Huntsman D. Germline E-cadherin mutations in familial lobular breast cancer. *J Med Genet*. 2007 Nov;44(11):726-31. PubMed PMID:17660459; PubMed Central PMCID: PMC2752184.
37. Corso G, Roviello F, Paredes J, Pedrazzani C, Novais M, Correia J, Marrelli D, Cirnes L, Seruca R, **Oliveira C**, Suriano G. Characterization of the P373L E-cadherin germline missense mutation and implication for clinical management. *Eur J Surg Oncol*. 2007 Nov;33(9):1061-7. PubMed PMID: 17434710.
36. Svrcek M, El-Bchiri J, Chalastanis A, Capel E, Dumont S, Buhard O, **Oliveira C**, Seruca R, Bossard C, Mosnier JF, Berger F, Leteurtre E, Lavergne-Slove A, Chenard MP, Hamelin R, Cosnes J, Beaugerie L, Tired E, Duval A, Fléjou JF. Specific clinical and biological features characterize inflammatory bowel disease associated colorectal cancers showing microsatellite instability. *J Clin Oncol*. 2007 Sep 20;25(27):4231-8. PubMed PMID: 17878476.
35. Kaurah P, MacMillan A, Boyd N, Senz J, De Luca A, Chun N, Suriano G, Zaor S, Van Manen L, Gilpin C, Nikkel S, Connolly-Wilson M, Weissman S, Rubinstein WS, Sebold C, Greenstein R, Stroop J, Yim D, Panzini B, McKinnon W, Greenblatt M, Wirtzfeld D, Fontaine D, Coit D, Yoon S, Chung D, Lauwers G, Pizzuti A, Vaccaro C, Redal MA, **Oliveira C**, Tischkowitz M, Olschwang S, Gallinger S, Lynch H, Green J, Ford J, Pharoah P, Fernandez B, Huntsman D. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. *JAMA*. 2007 Jun 6;297(21):2360-72. Epub 2007 Jun 3. PubMed PMID: 17545690.
34. Preto A, Moutinho C, Velho S, **Oliveira C**, Rebocho AP, Figueiredo J, Soares P, Lopes JM, Seruca R. A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation. *Virchows Arch*. 2007 Jun;450(6):619-26. Epub 2007 May 9. PubMed PMID: 17487504.
33. **Oliveira C**, Velho S, Moutinho C, Ferreira A, Preto A, Domingo E, Capelinha AF, Duval A, Hamelin R, Machado JC, Schwartz S Jr, Carneiro F, Seruca R. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. *Oncogene*. 2007 Jan 4;26(1):158-63. Epub 2006 Sep 4. PubMed PMID: 16953233.

## 2006

32. Serpa J, Mesquita P, Mendes N, **Oliveira C**, Almeida R, Santos-Silva F, Reis CA, LePendu J, David L. Expression of Lea in gastric cancer cell lines depends on FUT3 expression regulated by promoter methylation. **Cancer Lett**. 2006 Oct 28;242(2):191-7. PubMed PMID: 16427187.
31. Pereira PS, Teixeira A, Pinho S, Ferreira P, Fernandes J, **Oliveira C**, Seruca R, Suriano G, Casares F. E-cadherin missense mutations, associated with hereditary diffuse gastric cancer (HDGC) syndrome, display distinct invasive behaviors and genetic interactions with the Wnt and Notch pathways in Drosophila epithelia. **Hum Mol Genet**. 2006 May 15;15(10):1704-12. Epub 2006 Apr 6. PubMed PMID: 16600987.
30. Frebourg T, **Oliveira C**, Hochain P, Karam R, Manouvrier S, Graziadio C, Vekemans M, Hartmann A, Baert-Desurmont S, Alexandre C, Lejeune Dumoulin S, Marroni C, Martin C, Castedo S, Lovett M, Winston J, Machado JC, Attié T, Jabs EW, Cai J, Pellerin P, Triboulet JP, Scotte M, Le Pessot F, Hedouin A, Carneiro F, Blayau M, Seruca R. Cleft lip/palate and CDH1/E-cadherin mutations in families with hereditary diffuse gastric cancer. **J Med Genet**. 2006 Feb;43(2):138-42. PubMed PMID: 15831593; PubMed Central PMCID: PMC2564630.
29. **Oliveira C**, Seruca R, Carneiro F. Genetics, pathology, and clinics of familial gastric cancer. **Int J Surg Pathol**. 2006 Jan;14(1):21-33. Review. PubMed PMID:16501831.

## 2005

28. **Oliveira C**, Moreira H, Seruca R, de Oliveira MC, Carneiro F. Role of pathology in the identification of hereditary diffuse gastric cancer: report of a Portuguese family. **Virchows Arch**. 2005 Feb;446(2):181-4. Epub 2004 Dec 11. PubMed PMID: 15735979.
27. **Oliveira C**, Velho S, Domingo E, Preto A, Hofstra RM, Hamelin R, Yamamoto H, Seruca R, Schwartz S Jr. Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer. **Oncogene**. 2005 Nov 17;24(51):7630-4. PubMed PMID: 16007118.
26. Velho S, **Oliveira C**, Ferreira A, Ferreira AC, Suriano G, Schwartz S Jr, Duval A, Carneiro F, Machado JC, Hamelin R, Seruca R. The prevalence of PIK3CA mutations in gastric and colon cancer. **Eur J Cancer**. 2005 Jul;41(11):1649-54. PubMed PMID: 15994075.
25. Domingo E, Niessen RC, **Oliveira C**, Alhopuro P, Moutinho C, Espín E, Armengol M, Sijmons RH, Kleibeuker JH, Seruca R, Aaltonen LA, Imai K, Yamamoto H, Schwartz S Jr, Hofstra RM. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. **Oncogene**. 2005 Jun 2;24(24):3995-8. PubMed PMID: 15782118.
24. Gorringe KL, Chin SF, Pharoah P, Staines JM, **Oliveira C**, Edwards PA, Caldas C. Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer. **Carcinogenesis**. 2005 May;26(5):923-30. PubMed PMID: 15677628.

## 2004

23. **Oliveira C\***, Westra JL, Arango D, Ollikainen M, Domingo E, Ferreira A, Velho S, Niessen R, Lagerstedt K, Alhopuro P, Laiho P, Veiga I, Teixeira MR, Ligtenberg M, Kleibeuker JH, Sijmons RH, Plukker JT, Imai K, Lage P, Hamelin R, Albuquerque C, Schwartz S Jr, Lindblom A, Peltomaki P, Yamamoto H, Aaltonen LA, Seruca R, Hofstra RM. Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. **Hum Mol Genet**. 2004 Oct 1;13(19):2303-11. Epub 2004 Aug 4. PubMed PMID: 15294875.
22. **Oliveira C\***, Ferreira P, Nabais S, Campos L, Ferreira A, Cirnes L, Alves CC, Veiga I, Fragoso M, Regateiro F, Dias LM, Moreira H, Suriano G, Machado JC, Lopes C, Castedo S, Carneiro F, Seruca R. E-Cadherin (CDH1) and p53 rather than SMAD4 and Caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients. **Eur J Cancer**. 2004 Aug;40(12):1897-903. PubMed PMID: 15288293.
21. **Oliveira C**, Suriano G, Ferreira P, Canedo P, Kaurah P, Mateus R, Ferreira A, Ferreira AC, Oliveira MJ, Figueiredo C, Carneiro F, Keller G, Huntsman D, Machado JC, Seruca R. Genetic screening for familial gastric cancer. **Hered Cancer Clin Pract**. 2004 May 15;2(2):51-64. Doi: 10.1186/1897-4287-2-2-51. PubMed PMID:20233471; PubMed Central PMCID: PMC2839995.
20. **Oliveira C**, de Bruin J, Nabais S, Ligtenberg M, Moutinho C, Nagengast FM, Seruca R, van Krieken H, Carneiro F. Intragenic deletion of CDH1 as the inactivating mechanism of the wild-type allele in an HDGC tumour. **Oncogene**. 2004 Mar 18;23(12):2236-40. PubMed PMID: 14661064.

19. Domingo E, Espín E, Armengol M, **Oliveira C**, Pinto M, Duval A, Brennetot C, Seruca R, Hamelin R, Yamamoto H, Schwartz S Jr. Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. **Genes Chromosomes Cancer**. 2004 Feb;39(2):138-42. PubMed PMID: 14695993.

## **2003**

18. **Oliveira C**<sup>#</sup>, Pinto M, Duval A, Brennetot C, Domingo E, Espín E, Armengol M, Yamamoto H, Hamelin R, Seruca R, Schwartz S Jr. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. **Oncogene**. 2003 Dec 11;22(57):9192-6. PubMed PMID: 14668801.
17. Suriano G, Oliveira MJ, Huntsman D, Mateus AR, Ferreira P, Casares F, **Oliveira C**, Carneiro F, Machado JC, Mareel M, Seruca R. E-cadherin germline missense mutations and cell phenotype: evidence for the independence of cell invasion on the motile capabilities of the cells. **Hum Mol Genet**. 2003 Nov 15;12(22):3007-16. PubMed PMID: 14500541.
16. Brennetot C, Duval A, Hamelin R, Pinto M, **Oliveira C**, Seruca R, Schwartz S Jr. Frequent Ki-ras mutations in gastric tumors of the MSI phenotype. **Gastroenterology**. 2003 Oct;125(4):1282. PubMed PMID: 14552318.
15. Pinto M, Wu Y, Suriano G, Mensink RG, Duval A, **Oliveira C**, Carvalho B, Hamelin R, Seruca R, Hofstra RM. MBD4 mutations are rare in gastric carcinomas with microsatellite instability. **Cancer Genet Cytogenet**. 2003 Sep;145(2):103-7. PubMed PMID: 12935920.
14. Carvalho B, Pinto M, Cirnes L, **Oliveira C**, Machado JC, Suriano G, Hamelin R, Carneiro F, Seruca R. Concurrent hypermethylation of gene promoters is associated with a MSI-H phenotype and diploidy in gastric carcinomas. **Eur J Cancer**. 2003 Jun;39(9):1222-7. PubMed PMID: 12763209.
13. Pinto M, **Oliveira C**, Cirnes L, Carlos Machado J, Ramires M, Nogueira A, Carneiro F, Seruca R.J. Promoter methylation of TGFbeta receptor I and mutation of TGFbeta receptor II are frequent events in MSI sporadic gastric carcinomas. **J Pathol**. 2003 2003 May;200(1):32-8. PubMed PMID: 12692838.
12. Suriano G\*, **Oliveira C**\*, Ferreira P, Machado JC, Bordin MC, De Wever O, Bruyneel EA, Moguilevsky N, Grehan N, Porter TR, Richards FM, Hruban RH, Roviello F, Huntsman D, Mareel M, Carneiro F, Caldas C, Seruca R. Identification of CDH1 germline missense mutations associated with functional inactivation of the E-cadherin protein in young gastric cancer probands. **Hum Mol Genet**. 2003 Mar 1;12(5):575-82. PubMed PMID: 12588804.
11. **Oliveira C**, Seruca R, Caldas C. Genetic screening for hereditary diffuse gastric cancer. **Expert Rev Mol Diagn**. 2003 Mar;3(2):201-15. Review. PubMed PMID: 12647996.
10. Serpa J, Almeida R, **Oliveira C**, Silva FS, Silva E, Reis C, Le Pendu J, Oliveira G, Ribeiro LM, David L. Lewis enzyme (alpha1-3/4 fucosyltransferase) polymorphisms do not explain the Lewis phenotype in the gastric mucosa of a Portuguese population. **J Hum Genet**. 2003;48(4):183-9. Epub 2003 Mar 20. PubMed PMID: 12730721.

## **2002**

9. Sobrinho-Simões M, **Oliveira C**<sup>#</sup>. Different types of epithelial cadherin alterations play different roles in human carcinogenesis. **Adv Anat Pathol**. 2002 Nov;9(6):329-337. PubMed PMID: 12409641.
8. Carvalho R, Kayademir T, Soares P, Canedo P, Sousa S, **Oliveira C**, Leistenschneider P, Seruca R, Gött P, Blin N, Carneiro F, Machado JC. Loss of heterozygosity and promoter methylation, but not mutation, may underlie loss of TFF1 in gastric carcinoma. **Lab Invest**. 2002 Oct;82(10):1319-26. PubMed PMID: 12379766.
7. Pharoah PD, **Oliveira C**, Machado JC, Keller G, Vogelsang H, Laux H, Becker KF, Hahn H, Paproski SM, Brown LA, Caldas C, Huntsman D. CDH1 c-160a promotor polymorphism is not associated with risk of stomach cancer. **Int J Cancer**. 2002 Sep 10;101(2):196-7. PubMed PMID: 12209998.
6. **Oliveira C**, Bordin MC, Grehan N, Huntsman D, Suriano G, Machado JC, Kiviluoto T, Aaltonen L, Jackson CE, Seruca R, Caldas C. Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. **Hum Mutat**. 2002 May;19(5):510-517. PubMed PMID: 11968083.

## **2001**

5. Machado JC, Pharoah P, Sousa S, Carvalho R, **Oliveira C**, Figueiredo C, Amorim A, Seruca R, Caldas C, Carneiro F, Sobrinho-Simões M. Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. **Gastroenterology**. 2001 Oct;121(4):823-9. PubMed PMID: 11606496.



4. Machado JC, **Oliveira C**, Carvalho R, Soares P, Bex G, Caldas C, Seruca R, Carneiro F, Sobrinho-Simões M. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. **Oncogene**. 2001 Mar 22;20(12):1525-1528. PubMed PMID: 11313896.

#### **2000**

3. Pinto M, **Oliveira C**, Machado JC, Cirnes L, Tavares J, Carneiro F, Hamelin R, Hofstra R, Seruca R, Sobrinho-Simões M. MSI-L gastric carcinomas share the hMLH1 methylation status of MSI-H carcinomas but not their clinicopathological profile. **Lab Invest**. 2000 Dec;80(12):1915-23. PubMed PMID: 11140703.

#### **1999**

2. Caldas C, Carneiro F, Lynch HT, Yokota J, Wiesner GL, Powell SM, Lewis FR, Huntsman DG, Pharoah PD, Jankowski JA, MacLeod P, Vogelsang H, Keller G, Park KG, Richards FM, Maher ER, Gayther SA, **Oliveira C**, Grehan N, Wight D, Seruca R, Roviello F, Ponder BA, Jackson CE. Familial gastric cancer: overview and guidelines for management. **J Med Genet**. 1999 Dec;36(12):873-80. PubMed PMID: 10593993; PubMed Central PMCID: PMC1734270.

#### **1998**

1. **Oliveira C**, Seruca R, Seixas M, Sobrinho-Simões M. The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different "target genes": a study of the TGFbeta RII, IGFII R, and BAX genes. **Am J Pathol**. 1998 Oct;153(4):1211-9. Review. PubMed PMID: 9777952; PubMed Central PMCID: PMC1853052.

#### **BOOK CHAPTERS (n=8)**

8. Carneiro F, Guilford P, **Oliveira C**, van der Post RS. "Genetic tumour syndromes of the digestive system-Hereditary diffuse gastric cancer" in **WHO Classification of Tumours**, 5th Edition, Volume 1, page 535 to 538. Histopathology, 2019.
7. Leite M, Corso G, Sousa S, Carvalho J, Roviello F, **Oliveira C**, Figueiredo C, Seruca R. "Non - CDH1 - associated familial gastric cancer and epigenetics factors" In **Spotlight on Familial and Hereditary Gastric Cancer**. Springer, Dordrecht 2013, page 111 to 125. Doi: 10.1007/978-94-007-6570-2\_10.
6. Carvalho J, Pinheiro H, **Oliveira C**. "E-cadherin germline mutations" In **Spotlight on Familial and Hereditary Gastric Cancer**. Springer-Verlag GmbH 2013.
5. Pinheiro H, Carvalho J, **Oliveira C**. "Alternative mechanisms to germline CDH1 mutations in hereditary diffuse gastric cancer" In **Spotlight on Familial and Hereditary Gastric Cancer**. Springer-Verlag GmbH 2013.
4. **Oliveira C**, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. "E-cadherin alterations in hereditary disorders with emphasis on hereditary diffuse gastric cancer". *Prog Mol Biol Transl Sci*. 2013;116:337-59. Doi:10.1016/B978-0-12-394311-8.00015-7. PubMed PMID: 23481202.
3. Carneiro F, **Oliveira C**, Seruca R. "Hereditary Diffuse Gastric Cancer and Other Gastric Cancers Associated with Hereditary Predisposition Syndromes". In **Molecular Pathology of Neoplastic Gastrointestinal Diseases**. Part II Epithelial Neoplastic Disease, Chapter 6. Page 83. Springer, 2013.
2. Velho S, **Oliveira C**, Seruca R. "PIK3CA Gene Alterations in Human Cancers". In **Bioinformatics in Cancer and Cancer Therapy**. Series: Cancer Drug Discovery and Development. Gordon, Gavin J. (Ed.), 2009.
1. Karam R, **Oliveira C**, Seruca R, Carneiro F. "Câncer Gástrico Hereditário". In **Atualização em Câncer Gástrico**. Cap. 8, pág. 109. Tecmed Editora 2005.